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Abstract

DELIVERY OF SMOKE TOXICANTS FROM CIGARETTES MADE IN DEVLOPED
AND DEVELOPING COUNTRIES: A COMPARISON OF U.S. FULL FLAVOR AND
ULTRA LIGHT BRANDS WITH SYRIAN CIGARETTES.
By Lynn M. Anderson, B.A.
A thesis defense submitted in fulfillment of the requirements for the degree of Masters of
Science at Virginia Commonwealth University
Virginia Commonwealth University, 2005
Major Director: Thomas E. Eissenberg, Ph.D., Associate Professor, Department of
Psychology and Institute for Drug and Alcohol Studies

Clinical research is needed to understand how cigarette toxicant yield affects
smoker toxicant exposure. While there is much clinical research on yield and exposure in
developed countries, there is little in developing countries.
Forty smokers completed one, 4-hour session to compare yield and exposure of
different cigarettes. Participants smoked three cigarettes under controlled topography
conditions: one U.S. 111 flavor, one U.S. ultra light, and one Syrian cigarette, with 90
minutes between cigarettes. Sessions differed by Syrian brand; 2 1 participants smoked

Alhamraa while 19 smoked A1 Sham cigarettes. Blood nicotine and breath CO samples
were obtained, HR was monitored and subjective withdrawal and cigarette effect
questions were asked.
Results suggest that Syrian Alhamraa and U.S. full flavor were similar in
exposure while Syrian A1 Sham and U.S. ultra light were similar. Though U.S. full flavor
and ultra light cigarettes differed in toxicant yield and exposure, subjective ratings of
withdrawal were similar.
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Chapter 1
Introduction

Overview
The leading cause of preventable death in the world is tobacco smoking. Roughly
13,500 deaths occur every day from tobacco-related diseases, with a total of 4.9 million
tobacco-related deaths occurring globally each year (World Health Organization [WHO],
2004). These deaths have several causes, including cancer, cardiovascular disease, and
lung disease (WHO, 1997; Taylor & Bettcher, 2000; Centers for Disease Control [CDC],
2004). The number of tobacco-related deaths worldwide is projected to increase to 10
million per year by the year 2030 (WHO, 2004). If changes are not made, these trends
are expected to continue, with 1 billion people across the globe dying from tobaccorelated diseases by the end of the twenty-first century (Peto & Lopez, 2000). Thus,
cigarette smoking is an increasingly important global health threat.
The detrimental effects of smoking on global health are likely to be particularly
devastating in developing countries. In the year 2000,2.43 million smoking-related
deaths occurred in developed countries, and 2.41 million occurred in developing
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countries (Ezzati & Lopez, 2003). By 2030, 70% of smoking-related deaths worldwide
will likely occur in developing countries (WHO, 2004). Unfortunately, despite the
lethality of the tobacco epidemic, and the expectation that developing countries will soon
bear the brunt of it, most tobacco science has been limited to developed nations.
The high mortality rates for tobacco smokers are due to the many toxic smoke
constituents they inhale: cigarette smoke contains over 4,000 constituents, 60 of which
are known or suspected carcinogens, including polycyclic aromatic hydrocarbons and
tobacco-specific nitrosamines (United States Department of Health and Human Services
[USDHHS], 1988; Hoffmann, Djordjevic, & Hoffman, 1997). Many of these
carcinogens and other constituents are grouped under the heading "tar" (Federal Trade
Commission [FTC], 2000). Carcinogen doses per cigarette are small, but they accumulate
over a lifetime, thus increasing smokers' cancer risk dramatically (Hecht, 2002).
Another component of cigarette smoke that causes adverse health effects is
carbon monoxide (CO). CO has been implicated in cardiovascular disease, with smokers
being twice as likely to die of coronary heart disease relative to non-smokers (Epstein &
Perkins, 1988). Despite knowledge of these well known health risks, about 23% of the
U.S. population (CDC, 2003), and 59% of the global population (WHO, 1997) smoke
tobacco cigarettes. Continued smoking despite known health risks may be the result of
dependence upon one or more tobacco smoke constituents.
Nicotine is a tobacco smoke constituent and mild psychomotor stimulant that
supports physical dependence in non-human animals (USDHHS, 1988; Malin, Lake,
Newlin-Maultsby, Roberts, Lanier, Carter, et al., 1992) and humans (USDHHS, 1988;
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Benowitz, 1999). In humans, nicotine dependence is revealed during periods of tobacco
abstinence, when a withdrawal syndrome produces somatic signs (e.g., bradycardia,
increased food intake) and affective symptoms (e.g., anxiety, restlessness, depressed
mood; Hughes, Gust, Skoog, Keenan, & Fenwick 1991; American Psychological
Association [APA], 1994). Not surprisingly, 77-92% of tobacco smokers are dependent
upon nicotine (Douglas, 1997). Nicotine dependence can contribute to smoking-related
death and disease because it makes quitting difficult. For example, 70% of American
smokers report that they want to quit, and 30% will attempt to quit each year. However,
only 3% of those who attempt to quit will be successful after one year (Benowitz, 1999).

In samples of smokers in other countries, the percentage able to maintain long-term
abstinence is similar (e.g., 5% in India, China, and Syria; Gupta, 1996; Yang, Ma, Chen,
Zhang, Samet, Taylor, et al., 2001; Maziak, 2002). The aversive withdrawal symptoms
that accompany a quit attempt likely contribute to these relatively low cessation rates,
especially considering that relapse to cigarette use is an effective method for suppressing
these symptoms (USDHHS, 1988).
Overall, tobacco smoking is a global issue that produces serious adverse health
effects via carcinogen and CO intake and that is maintained, at least in part, by nicotine
dependence. One step in addressing this health problem involves gaining an
understanding of the levels of nicotine and other smoke toxicants that cigarettes yield and
to which smokers are exposed. A great deal of this research has been conducted in the
U.S. and other developed countries, though the extent to which these results generalize to
cigarettes and smokers in developing countries is unknown. This research from the U.S.
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and developed countries is reviewed below, with a primary emphasis on CO and nicotine.
A similar review is then conducted with research from developing countries.
Smoke Toxicants that Cigarettes in Developed Countries Yield and to Which Smokers in
Developed Countries are Exposed

There is much research on the constituent yield of tobacco smoke that is produced
by cigarettes manufactured and marketed in developed countries llke the U.S., Canada,
and the United Kingdom [U.K.]. The constituents most often measured in cigarettes that
are marketed in these countries include carcinogens, CO, and nicotine. One method of
measuring smoke toxicant yield was developed by the U.S. Federal Trade Commission
(FTC) and involves the use of smoking machines to "smoke" cigarettes in a prescribed
manner so that different brands can be compared (Pillsbury, Bright, O'Connor, & Irish,
1969). Using the FTC method, a cigarette is placed in one of several smoking machine
ports. The cigarette is lit and the machine draws 35 ml, 2 sec duration "puffs" with an
inter-puff-interval ( P I = time between puffs) of 58 sec until one of two conditions is met
(whichever takes more time): either a butt length of 23 rnm is reached or the cigarette has
burned to within 3 rnrn of the edge of the tipping paper (Pillsbury et al., 1969). As the
puffs are drawn, particulate matter from the smoke is collected onto a filter pad, and
gases that pass through the pad are also collected. Thus, the FTC method allows for
measurement of smoke toxicant y&l

in terms of milligrams of nicotine-free dry

particulate matter (NFDPM; found in the pad), CO (measured in the gases that pass
through the pad), and nicotine (found in the pad). One disadvantage of the FTC method
is that smoke toxicant yields do not always predict smoke toxicant exposure in smokers,
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as measured in exhaled breath and/or body fluids (saliva, urine, or blood; Kozlowski,
Rickert, Pope, Robinson, & Frecker, 1982; Herning, Jones, Benowitz, & Mines, 1983).
Thus the sections below discuss the smoke toxicant yield of cigarettes marketed in the
U.S. and the smoke toxicant exposure of U.S. smokers. Subsequent sections will discuss
yield and exposure from cigarettes and smokers in developing countries.
Carcinogens that cigarettes in developed countries yield and to which smokers in
developed countries are exposed. Cigarette smoke contains over 60 carcinogens

(Hoffman et al., 1997). Some of these carcinogens are tobacco specific nitrosamines
(TSNAs) such as N-nitrosonornicotine (NNN), N-nitrosoanatabine (NAT), and 4(methy1nitramino)-1-(3-pyridy1)-1-butanone (NNK) (Swauger, Steichen, Murphy, &
Kinsler, 2002) and others are polycyclic aromatic hydrocarbons (PAHs) such as
benzo[a]pyrene (BaP), dibenz[a,h]anthracene, and 5-methylchrysene (Zevin, Gourlay, &
Benowitz, 1998; Hecht, 1999). Because carcinogens are so numerous in cigarette smoke,
they are seldom measured individually, and the carcinogenic compounds in cigarette
smoke are reported as either NFDPM or, more commonly, as "tar".
As can be seen in Table 1, the tar levels of U.S. cigarettes differ by brand type,
with so-called "full flavor" brands yielding significantly more tar than so-called "light"
brands, which, in turn, yield significantly more tar than so-called "ultra-light'' brands (full
flavor, light, and ultra light are defined by FTC yields). Light and ultra light cigarettes
are made by using specific tobacco blends, differing filter tips, and porous filter paper
and/or filter ventilation holes that dilute the smoke. By the 1990's, over 90% of U.S.
cigarettes were filtered, and 50% of these filters had ventilation holes (National Cancer

6
Institute [NCI], 2001). The resulting difference in tar yield of light and ultra light brands,
often noted in cigarette advertisements, led many U.S. smokers to believe that these
brands reduced carcinogen exposure, relative to full flavor brands (NCI, 1996). Not
surprisingly then, smokers purchased cigarettes with lower tar yields: the sales-weighted
average tar yield decreased from 38 mg in 1954 to 12 mg in 1993 (Hoffman et al., 1997;
NCI, 1996). Interestingly, many smokers chose these cigarettes with the belief that they
would inhale smoke with lower toxicant levels (Giovino et al., 1996). Also, smokers who
were not able to quit smoking were urged to smoke these brands as a means of reducing
their carcinogen exposure (Kozlowski et al, 1982). Thus, there was some expectation
that reductions in the tar yield of cigarettes purchased and smoked by U.S. smokers might
have been associated with reduced rates of smoking-related cancer.
Though 63% of men and 84% of women smokers in the U.S. smoke lighthltra
light cigarette brands, cancer rates have not decreased accordingly (NCI, 1996, 2001).
This failure of low tar cigarette use to lower cancer rates was highlighted in one study in
which data were analyzed from studies that followed smokers in two cohorts (cohort I
enrolled in 1959 and cohort I1 enrolled in 1982) and observed their lung cancer rates.
Results indicate that despite the decrease in FTC tar yields, lung cancer rates have
increased since the 1950's, and the increase in lung cancer rates across cohorts suggest
that reducing tar yield reduces neither carcinogen exposure nor lung cancer rates (Thun &
Heath, 1997). Thus, epidemiological data suggest that analysis of cigarette smoke
produced by smoking machines (as in the FTC method) is insufficient for understanding
smokers' exposure to cigarette-deliveredtoxicants.
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Several exposure studies support the notion that smokers' carcinogen exposure
cannot be predicted by smoke toxicant yield (Russel, Jarvis, Iyer, & Feyerband, 1980;
Kozlowski et al., 1982; Djordjevic, Hoffman, & Hoffman, 1997; Djordlevic, Stellman, &
Zang, 2000; NCI, 2001 ; Woodward & Tunstall-Pedoe, 1992). One of the reasons that
FTC yield is a poor predictor of exposure is that smokers do not adhere to the FTC
method. Indeed, in most studies of smokers, variables such as puff volume and P I are
different from the FTC method, and show considerable variability across subjects. In
yield and exposure studies, puff topography assessment (i.e., measurement of puff
volume, puff duration, puff number, and P I ) reveals that puff parameters determine the
tar, nicotine, and CO yield and exposure.
For example, when low tar cigarettes are "smoked" by machines using FTC
parameters versus using human parameters, the estimated tar deliveries do not match.
One study addressing this point measured the puff topography (puff volume and P I ) of
smokers of low tar yield cigarettes and then set a smoking machine to these parameters
(Djordjevic et al., 2000). As compared to FTC parameters, humans took larger puffs
(average puff volume of 48.6 ml low-yield vs. 35 ml FTC) and had shorter P I S (21.3 sec
low-yield vs. 58 sec FTC). As a result, the mean tar yield for human parameters was 22.3
mglcig (geometric mean; 95% confidence interval = 18.8 - 26.5), a full 13.8 mglcig
higher, on average, than the tar yields derived from the FTC parameters (geometric mean
= 8.5 mglcig; 95% confidence interval = 7.7-9.5; Djordjevic et al., 2000). These

differences in tar yield observed using the FTC method and more realistic smoking
parameters reflect differences in the yield of specific carcinogens. For example, the
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yields of the carcinogens BaP and NNK from low yield cigarettes can increase relative to
FTC yields when smoking parameters are more realistic. The yield of BaP was 7.9
mg/cig higher under human parameters than the yield derived from FTC methods
(geometric mean = 17.9 mglcig; 95% confidence interval = 15.3-20.9). NNK yield was
73.6 mglcig higher under human parameters than the yield derived from FTC methods
(geometric mean = 186.5 mglcig; 95% confidence interval = 158.3-219.7; Djordjevic et
al., 2000).
The FTC method also underestimates tar and carcinogen yield across mediumyield cigarettes (Djordjevic et al. 2000). The yield of BaP was 7.4 mglcig higher under
human parameters (geometric mean = 21.4 mg/cig; 95% confidence interval = 19.2-23.7)
than the yield derived from FTC methods (geometric mean = 14.0 mglcig; 95%
confidence interval = 10.1-19.4). NNK yield was 104.7 mglcig higher under more
realistic parameters (geometric mean = 250.9 mglcig; 95% confidence interval = 222.7282.7) than the yield derived from FTC methods (geometric mean = 146.2 mg/cig; 95%
confidence interval = 132.5-161.3; Djordjevic et al. 2000). Thus, tar yield may
communicate some information regarding carcinogen yield, although the FTC method
clearly does not communicate real-world values. Human puffing parameters may convey
more realistic values.
However, puff topography values can vary considerably and systematically
between subjects. Indeed, smokers' gender is an important factor: men take significantly
larger (mean=54.8 ml, SEM=2.5) and longer puffs (mean=1.53 sec, SEM=0.08) than
women (mean=41.61 ml, SEM=2.8, mean=l .19 sec, SEM=0.09) (Eissenberg, Adams,
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Riggins, & Likness, 1999). These differences need to be taken into account when
studying cigarette yields.
Another reason that FTC yield is a poor predictor of exposure is that smokers
cover some or all of the ventilation holes in a cigarette filter with lips or fingers when
they smoke (e.g., Kozlowski et al., 1982). Covering ventilation holes does not allow the
smoke that is inhaled by the smoker to be diluted with the surrounding air, as it is using
the FTC method. In one study that examined this issue, smoke constituent levels of
eleven low yield brands were determined using standard FTC machine smoking and nonstandard machine smoking where the parameters were set to the sample population's
average puff volume (47 ml), duration (2.4 sec) and P I (44 sec) with filter ventilation
holes occluded with tape. Relative to FTC methods (mean tar yield = 0.7 mglcig; SD =
0.2), tar yields obtained from cigarettes smoked under non-standard parameters and with

blocked ventilation holes were higher (mean tar yield = 17.5 mglcig; SD = 6.7). Thus,
the combined influence of realistic smoking parameters and blocked ventilation holes
results in a dramatic increase in tar yield (i.e., mean difference in tar yield = 16.8 mglcig;
SD = 6.6; Kozlowski et al., 1982).
As the above studies have shown, smokers of low yield cigarettes may be
exposed to higher levels of carcinogens than predicted by the FTC. Another way to
observe this apparent increase in exposure is to measure biomarkers of exposure (blood,
saliva, or urine). In a study that used these methods, daily smokers smoked ten cigarettes
from each of three brand types: low tar yield, medium tar yield, and high tar yield
(Mohtashamipur, Norpoth, & Lieder, 1987). Urine samples were collected and examined
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for mutagenic activity (causing genetic mutation). Mutagenic activity levels in the urine
were higher when smokers smoked the low tar yield cigarettes than when they smoked
medium or high tar yield cigarettes. Unfortunately, puff topography was not controlled,
thus the influence of changes in smoking behavior on these increases in urine mutagenic
levels after smoking low yield cigarettes is uncertain (Mohtashamipur et al., 1987).
Regardless of the mechanism, these results do not support the notion that carcinogen
exposure is lowered when smokers smoke low-yield cigarettes.
Another study collected and analyzed urine samples from smokers of regular,
light, and ultra light cigarettes to determine if smokers of these different types of
cigarettes are exposed to different levels of 1-HOP and NNAL (biomarkers for lung
cancer). Published tar levels for these cigarettes were compared with the biomarkers to
examine possible tar delivery differences between the different types of cigarettes.
Urinary cotinine levels were also compared. No significant differences were found in
either the 1-HOP or NNAL levels found in the smokers of different types of cigarettes
and no correlation was found between published tar levels and corresponding biomarker
delivery. Also, the urinary cotinine levels that the different smokers were exposed to
were not significantly different (Hecht, Murphy, Carmella, Li, Jensen, Le, et al., 2005).
The results do not support the notion that light cigarettes expose smokers to lower levels
of carcinogens than regular cigarettes.
Another study observed biomarkers of exposure in order to estimate tar delivery
in smokers of cigarettes with differing tar levels (Woodward & Tunstall-Pedoe, 1992).
Smokers were classified into three categories based on the machine-smoking tar yields of
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the cigarettes that they usually smoked: high tar (mean = 15.7 mglcig), middle tar (13.3
mglcig), and low tar (7.77 mglcig). Blood samples were obtained from smokers of
cigarettes within each tar level group to examine cotinine and thiocyanate (a metabolite
of hydrogen cyanide) levels and breath samples were obtained to determine CO levels.
These levels were used to calculate the estimated tar exposure. Number of cigarettes
smoked per day was not controlled for. Results indicated that smokers of relatively low
tar cigarettes do indeed consume less tar for the same number of cigarettes smoked, but
the decrease is much less than the official yields would suggest. The consumption of
other smoke components may not be less amongst those smoking relatively low tar
cigarettes, and may even be higher when we compare a middle tar smoker with a high tar
smoker (Woodward & Tunstall-Pedoe, 1992; p. 927).
Thus, although smokers of lower tar cigarettes may receive less tar, this reduction
is not proportional to machine smoking yields.
In summary, in developed countries, tar yield (and thus carcinogen yield) is
measured by the FTC or other machine smoked method, and is related to cigarette brand
(i.e., full flavor, light, ultra light). Few studies have investigated carcinogen exposure in
smokers directly (i.e., by measuring carcinogens or carcinogen metabolites in smokers
blood or urine). However, epidemiological and laboratory data suggest that carcinogen
exposure is high in this population, and that exposure is not predicted accurately by FTC
yield. FTC yield is not a good predictor for several reasons, including the fact that
smokers do not smoke according to FTC smoking parameters and block filter ventilation
holes when smoking. As Woodward & Tunstall-Pedoe (1992) conclude, differences
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between machine smoking tar yields and actual tar exposure are "likely to be extremely
important in diseases related to tar intake, such as lung cancer" (p. 925). Generally, then,
assessment of smoke constituent yield must be complemented by an assessment of smoke
constituent exposure in smokers, in order to attain a realistic estimate of disease rates. As
discussed below, this same general message is relevant to CO and nicotine yield and
exposure.

Table 1
Mean FTC yields of popular full flavor, light, and ultra light cigarette brands manufactured and
sold in the U.S.

Mean
Cigarette type

Tar

Nicotine

Sample Size
CO

N

Full Flavor

15.3(1.5)

1 .O(O.
15)

15.3(1.5)

8

Light

9.2(1.O)**

0.7(0.I)**

11.0(1.2)**

8

Ultra light

5.6(1.5)t

0.5(0.12)t

7.6(1.5)t

7*

Note. The average tar, nicotine, and CO levels (mg) for eight popular brands of U.S. cigarettes. Six of the
eight brands of cigarettes chosen for this analysis were listed as the most popular in the U.S. by the Centers
for Disease Control (CDC, 2004).
*The n of the ultra light cigarette type is less than the n of the full flavor and light cigarette types because
one brand is not produced in an ultra light version. ** Indicates a significant difference from full flavor
cigarettes at p < .001. t Indicates a significant difference from light cigarettes at p < .001.

CO levels that cigarettes from developed countries yield and to which smokers in
developed countries are exposed. CO is a gas that is produced when a material, such as

tobacco, is burned. CO is rapidly absorbed from the lungs into the blood stream where it
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binds with hemoglobin which would normally carry oxygen. Hemoglobin's affinity for
CO is over 200 times greater than it's affinity for oxygen. Therefore, CO binding to
hemoglobin reduces the amount of oxygen that is delivered to tissues throughout the
smokers' body, including the heart (Stewart, 1975; Lakier, 1992). This reduction in
oxygen delivery, in turn, causes the heart to pump harder to provide the body with
oxygen. Also, the majority of inhaled CO is eliminated, unchanged, from the lungs, with
less than 1% being metabolized to carbon dioxide in the body. CO has a half-life of 4-5
hours in a sedentary adult (Stewart, 1975).

In the U.S., the FTC method is used to determine a cigarette's CO yield and Table
1 shows that CO yield for U.S. cigarettes differ by cigarette type. As with tar yields, light

cigarettes deliver significantly less CO than full flavor cigarettes, and ultra light
cigarettes deliver significantly less CO than light cigarettes. Also as with tar yields, CO
yield does not predict CO exposure in smokers. As discussed previously, the difference
between FTC yield and smoker exposure is due, in part, to the fact that smokers do not
adhere to FTC smoking parameters (e.g. Djordjevic et al., 2000). As discussed below,
filter ventilation blocking and brand-induced changes in smoking behavior are also
relevant.
Cigarette brands have varying degrees of filter ventilation: full flavor cigarettes
generally have no ventilation and ultra light cigarettes generally have the greatest amount
of ventilation. Frequently, filter ventilation is accomplished with vents or holes that are
approximately 11-15 mm away from the end of the filter (NCI, 2001). Ventilation holes
allow air to mix with and dilute the smoke of a cigarette decreasing the amount of smoke
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that is inhaled (NCI, 1996). For example, a cigarette that has 60% ventilation will
generate a puff that is 60% air and 40% smoke (NCI, 2001). In one study of the
influence of ventilation hole blocking, smokers used brands of cigarettes which varied in
percent ventilation, ranging from 40% ventilation, (FTC CO yield = 9 mg) to 83%
ventilation (FTC CO yield = 1 mg; Sweeney, Kozlowski, & Parsa, 1999). Using ad lib
smoking, the cigarettes were either smoked with no ventilation holes covered or as many
ventilation holes as possible covered by the participants' fingers. Filter ventilation hole
blocking clearly influenced CO exposure in cigarettes with more ventilation. For
example, a significant increase was found in the mean CO boost (post-smoking CO
minus pre-smoking CO) of cigarettes with 66% ventilation after ventilation holes were
blocked (unblocked mean = 2.0 ppm; SEM = 0.57 versus blocked mean = 3.7 ppm; SEM
= 0.49). Results of this study suggest that the more ventilation a cigarette filter has, the

higher the increase in CO delivery if the smoker engages in ventilation hole blocking
(Sweeney et al., 1999).
Similar results were found in another study which examined the effects of
ventilation hole covering of ultra low yield cigarettes (FTC 1 mg CO) on CO levels in
smokers of medium to high yield cigarettes (Zacny, Stitzer, & Yingling, 1986). In two
experiments, ultra low yield cigarettes were smoked, each with a varying degree of
occluded ventilation holes: 0% occluded, 50% occluded, or 100% occluded. In
experiment one, eight cigarettes were smoked in the lab in each of three sessions under
controlled puffing parameters (i.e., 8 puffs, 1 puff every 50 sec, 60 ml puff volume, with
a breath hold duration of 3.5 sec) with a 20 min inter-cigarette interval. CO was
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measured immediately before and 2 min after smoking, in order to determine CO boost.
Results indicated that CO boost increased significantly as a function of percent of
ventilation holes covered with mean CO boost of 0.83 ppm, 2.87 ppm, and 7.07 ppm for
0%, 50%, and 100% ventilation holes covered, respectively (Zacny et al., 1986).
In experiment two, one cigarette from each of the ventilation occlusion conditions
was smoked in the lab under ad lib puffing conditions for a total of three cigarettes every
day for five days. Results indicated that CO boost increased significantly from pretrial
CO with mean CO boost of 4.32 ppm, 6.44 ppm, and 8.96 ppm for 0%, 50%, and 100%
ventilation holes covered, respectively. Mean puff volume increased as ventilation
occlusion decreased from 42.8 ml at 100% occlusion to 63.3 ml at 0% occlusion. Results
from these experiments suggest that smokers will increase the amount of smoke they
inhale when smoking cigarettes with ventilation holes. These smokers will therefore be
exposed to higher levels of CO than the FTC yields predict (Zacny et al., 1986).
Another study observed CO exposure in smokers of high-, medium-, and lowyield cigarettes (Woodward & Tunstall-Pedoe, 1992). Breath samples were obtained
from smokers of cigarettes within each tar level group to determine CO levels. Smokers
of low tar cigarettes were exposed to less CO than smokers of medium or high tar
cigarettes. Smokers of medium tar cigarettes (mean = 24.5; SD = 13.9), however, may be
exposed to higher CO levels than those who smoke high tar cigarettes (mean = 23.5; SD
= 13.1). These differences may be due to changes in smoking topography, but as no

topography measures were examined, it is difficult to explain these differences with any
certainty.
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In summary, much is known in developed countries about CO yield and delivery.
Brands that have low CO yield as determined using machine smoking methods do not
necessarily expose smokers to lower levels of CO. This failure to reduce exposure is
likely due to blockage of filter ventilation holes andlor changes in smoking topography.
Thus, an accurate assessment of a cigarette's ability to deliver CO to a smoker involves
measuring CO exposure in humans who are smoking.
Nicotine levels that cigarettes in developed countries yield and to which smokers
in developed countries are exposed. Nicotine is an agonist, a drug that triggers an action,

and it binds to nicotinic cholinergic receptors (Kilaru, Frangos, Chen, Gortler, Dhadwal,
Araim, et al., 2001; Rosenzweig, Breedlove & Leiman, 2002). These receptors are found
in the brain and the peripheral nervous system (Watkins, Koob & Markou, 2000).
Nicotine produces many effects such as mild euphoria (Pomerleau & Pomerleau, 1992),
heightened arousal, appetite suppression, reduction of stress (Benowitz, 1996), body
weight regulation, and mood (e.g., anxiety and tension; Palfai & Jankiewicz, 1997).
Once in the brain, nicotine binds to acetylcholine receptors triggering the release of
serotonin, acetylcholine, norepinephrine, and dopamine neurotransmitters. The release of
serotonin in the brain reduces negative affect and anxiety (Benowitz, 1999; Royal
College of Physicians, 2000). Acetylcholine release affects memory and performance.
Nicotine-induced release of norepinephrine (and epinephrine) from the adrenal glands
results in increased heart rate and blood pressure. Dopamine release creates feelings of
pleasure and the effects of this neurotransmitter may be one of the main reasons for the
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positive reinforcing effects of cigarettes (Pomerleau & Pomerleau, 1984; Royal College

of Physicians, 2000).
Nicotine is believed to be the tobacco smoke constituent that is responsible for
maintaining tobacco use in humans, primarily because nicotine administration is
reinforcing and repeated nicotine administration can produce physical dependence
(USDHHS, 1988; Stolerman & Jarvis, 1995; Benowitz, 1999; Eissenberg, 2004). The
most efficient delivery device of nicotine is the cigarette (Benowitz, 1996), and a
majority of cigarette smokers eventually become nicotine dependent (Balfour, 1994;
Stolerman, 1991). Nicotine dependence can be revealed by an aversive withdrawal
syndrome experienced during periods of tobacco abstinence (Hughes & Hatsukami,
1986). Withdrawal symptoms can begin within minutes after cessation (Schuh & Stitzer,
1995), peak within 1 - 4 days after cessation (Hatsukami, Hughes, Pickens, & Svikis,
1984; Buchhalter, 2002) and may include headache, irritability, sleep disturbances, an
inability to concentrate, and hunger (Hughes & Hatsukami, 1986). The maintenance of
regular tobacco smoking is thought to be facilitated by the avoidance or suppression of
withdrawal symptoms through nicotine administration (Watkins et al., 2000; USDHHS,
1988; Eissenberg, 2004).
As with tar and CO, Table 1 shows that, in the U.S., FTC cigarette nicotine yields
differ by brand: full flavor cigarettes have higher average nicotine yields than light
cigarettes which have higher nicotine yields than ultra light cigarettes. And, as with CO,
FTC yields are poor predictors of smokers' nicotine exposure (Herning et al., 1983;
Russell et al., 1980). For example, in one study eleven daily smokers (2 40 ciglday) were
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asked to smoke two cigarettes during each laboratory visit for a total of 40 cigarettes
smoked over a total of 20 days (Herning et al., 1983). The smoking sessions occurred in
the laboratory setting and puff topography was measured. The first cigarette of a session
was always a standardized research cigarette that contained more (2.5 mg) or less (0.4
mg) nicotine, as measured by the FTC method, than the smoker's usual brand (mean =
1.0 mg; SD = 0.2). The other brand was the smoker's own brand and was smoked at the
request of the smoker (mean + SD = 18.5 + 8.2 min inter-cigarette-interval). Blood was
sampled 60-120 sec before and 30-120 sec after smoking. Results indicated that machine
predicted nicotine yield and actual nicotine delivery were only moderately correlated (r =
0.50) and the remaining variability in blood nicotine level was accounted for largely by
individual differences in smoking behavior (Herning et al., 1983).
One factor that contributes to the poor predictive relationship between FTC
nicotine yield and smokers' nicotine exposure is the fact that smokers regulate their daily
intake of nicotine (NCI, 2001): smokers of low and medium nicotine yield cigarettes
smoke with more intensity by increasing their puff volume than smokers of high nicotine
cigarettes (Djordjevic et al., 1997). This effect is most readily observed in the laboratory
when smokers are provided with cigarettes that have lower FTC nicotine yields than their
usual brand. For example, in one study of 26 daily, full flavor brand smokers (mean of
24 ciglday), twelve participants were given ultra low yield cigarettes (0.1 mg nicotine)
and were asked to smoke only these cigarettes for ten days (West & Gossop, 1994). The
other fourteen participants smoked their usual brand of full flavor cigarettes (1.3 mg
nicotine) for ten days. Blood samples were taken to measure nicotine levels in both
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groups. All participants reported smoking the same number of cigarettes per day (mean
of 23.8 ciglday in the low yield condition vs. 22.3 in the full flavor condition). While
nicotine levels were lower in the ultra low yield condition (mean of 3 days = 10.5 nglml)
than in the full flavor condition (mean of 3 days = 33.2 nglml), the levels were not as low
as might be predicted using FTC nicotine levels (e.g., smoking a 0.1 mg nicotine cigarette
instead of a 1 mg nicotine cigarette is a tenfold reduction in nicotine yield). Nicotine
exposure that differs from that predicted using FTC yield could be due to changes in
smoking behavior. In other words, these smokers may have increased their puff volume,
duration, and/or P I when using ultra low yield cigarettes in an attempt to maintain their
usual nicotine exposure (West & Gossop, 1994).
Another study (Zacny & Stitzer, 1988) revealed similar results. Ten daily
smokers (mean 30.5 ciglday) who normally smoked full flavor brand cigarettes were
given four brands of cigarettes of differing nicotine yields, as well as their own brand,
over a period of five weeks. In each five-day period, the participants smoked a different
yield brand: ultra low yield (0.1 mg), low yield (0.4 mg), medium yield (0.7 mg), high
yield (1.1 mg), and own brand (1.0 mg). They smoked cigarettes ad lib and returned all
butts and unused cigarettes to the laboratory each week. Topography measures and blood
samples were obtained when participants smoked in the laboratory on the first and last
day of each week. Results indicated that daily cigarette consumption (own brand mean =
30.5 cpd vs. ultra low yield = 34.3 cpd), puff volume (own brand mean = 53.4 ml vs.
ultra low yield = 64.7 ml), and number of puffs (own brand mean = 6.8 vs. ultra low yield
= 11.3 puffslcigarette) increased from own brand when participants smoked ultra low
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yield cigarettes. Blood nicotine level reductions were not well predicted by FTC yields
(e.g., a 90% reduction would be predicted when smoking 0.1 mg nicotine yield cigarettes,
as compared to an observed reduction of 67%) which may be due to the observed
changes in number of cigarettes smoked and/or smoking topography. These full flavor
smokers may have changed their smoking behavior in order to maintain their exposure to
nicotine when smoking lower nicotine yield cigarettes (Zacny & Stitzer, 1988).
Cigarettes in developed countries: summary of carcinogen, CO, and nicotine
yield and exposure. There is a large body of evidence in the U.S. and other developed

countries that smoke from cigarettes contains many toxic constituents and that the
machine derived yields of these constituents do not reveal the actual constituent exposure
in smokers. This discrepancy is almost certainly due to changes in smoking topography
and ventilation hole blocking. In essence, people do not smoke according to the FTC
method, but instead alter their smoking behavior in ways that negate cigarette design
changes and that produce smoke constituent yields that differ from those produced using
the FTC method. These alterations in smoking behavior may be due to a failure of some
cigarette types (i.e., low yield cigarettes) to suppress withdrawal effectively (e.g., West &
Gossop, 1994). Interestingly, FTC yield might be a better predictor of exposure under
conditions where smokers' topography is held constant and where filter ventilation holes
cannot be blocked, though this hypothesis has not been tested.
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Smoke toxicants that cigarettes in developing countries yield and to which smokers in
developing countries are exposed

In developing countries, there is less literature available regarding yield and
exposure of smoke toxicants. A developing country is defined as a low- or middleincome country in which most people have a lower standard of living than most people in
high-income countries (The World Bank Group, 2004). Of the few studies that have been
conducted on cigarette constituent yields in developing countries, some were conducted
many years ago (e.g., studies on African cigarette constituent levels; Seftel, 1979;
Awotedu, Higenbottam, & Onadeko, 1983). However, cigarettes and smokers may have
changed in the intervening 25 years. Of the more recent studies, all have focused
primarily on the cigarette constituent yields as determined by machine methods (e.g.,
Mitacek, Brunnerman, & Polednak, 1990; Hamadeh, Dphil, McPherson, & Doll, 1994;
Pakhale & Maru, 1998; Ashley, Beeson, Johnson, McCraw, Richter, Pirkle et al., 2003).
Some results are consistent with the hypothesis that toxicant yields from cigarettes sold in
developing countries are higher than those from cigarettes made and sold in developed
countries (Mitacek et al., 1990; Firat, 1996; Ashley et al., 2003). One study showed no
difference in machine-smoked constituent yields of Marlboro brand cigarettes
manufactured in or exported to 35 different countries. In this case only the local
manufactured, non-Marlboro brands varied in yield, with Eastern Mediterranean and
Southeastern Asian regions having higher deliveries than those made in Europe and the
Americas (Calafat, Polzin, Saylor, Richter, Ashley, & Watson, 2004). A limitation of
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this study is that these yields were determined by machine smoking methods and cannot
predict actual exposure to the smoker.
Of the studies examining differing brands of cigarettes in developing countries, no
clinical research could be found that examined the exposure of smokers to cigarette
toxicants such as CO and nicotine.
Carcinogens that cigarettes in developing countries yield. Generally, smoke

toxicant yields can vary from country to country, even within the same brand (Seftel,
1979; Firat, 1996; Kozlowski, Mehta, Sweeney, Schwartz, Vogler, Jarvis, et a1.,1998;
Ashley et al., 2003). In Thailand, six brands of locally made cigarettes, several of which
were unfiltered, were analyzed to determine their FTC tar yields and these were
compared with the FTC yields of two normally-marketed U.S. brands (Mitacek et al.,
1990). The locally made, filtered brands yielded higher tar levels (21.3-28.1 mg) than the
U.S. filtered brands (10.3-26.4 mg) and the non-filtered brands yielded on average 8
mg/cig more tar (24.0 mg/cig +. 14.8) than the U.S. non-filtered brand (16.0 mg/cig). As
23% of the Thai population smokes cigarettes, higher tar levels could increase the rates of
tobacco-related disease in a country where 467,668 people died from such diseases in
1994 alone (Mitacek et al., 1990; WHO, 2003). Tar yields are also high in cigarettes
made and sold in Turkey (Firat, 1996). Several local and imported brands were measured
using International Organization for Standardization [ISO] methods, which are similar to
FTC methods, (one 35 ml puff, 2 sec in duration every 60 sec; NCI, 1996) to determine
the tar yield. The locally produced brands had a higher tar yield (1 1.8-29.2 mg) as
compared to the imported brands (7.23-17.1 mg). In addition, two of the fourteen locally
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produced brands were the only brands to have tar yields below 12 mg (the European
standard). When examining brands exported to both Turkey and the U.K., tar yields were
found to be higher by up to 4 mg in five of the seven brands that were exported to Turkey
(Firat, 1996). Though Turkey and the U.K. are importing the same brands, smokers in
Turkey may have a higher risk of developing tobacco-related cancer due to the higher tar
yields (to the extent that greater tar yields increase cancer risk).
A more recent study compared the machine-smoked yields of locally made
cigarette brands with Marlboro brand cigarettes either manufactured in or exported to
various countries (Calafat et al., 2004). Seventy-seven cigarette brands were obtained
from 35 countries, of which 97% of the brands were filtered and 95% were nonmentholated. The cigarettes were machine-smoked according to FTC methods. The
average 13.4 mg (SD = 1.7) tar yield of Marlboro brand cigarettes was similar to the 14.4
mg (SD = 3.8) average of local brands. Results for cigarettes from 29 other developing
countries represented in this study are displayed in Table 2, which shows that the
individual and mean tar yields of these cigarettes approximate that of U.S. full flavor
brands (see Table 1 for U.S. brand tar yields). However, as noted in the report's
conclusion: ". . . an important limitation of this study is that people do not smoke
cigarettes as machines smoke them" (Calafat et al., 2004, p. 50). Thus, understanding the
carcinogen exposure of smokers in developing countries likely will involve clinical
evaluation.

Table 2
Toxicant yields of twenty-nine cigarette brands sold in developing countries.
Mean (SD) mglcigarette

S a m ~ l eSize

Developing
Country

1

Brazil

2

China

3

Cyprus

4

Egypt

5
6

Fiji
India

7

Jordan

8

Kenya

9
10

Kiribati
Lao P.D.R.

11

Lebanon

Tar

Nicotine

CO

Lithuania
Marshall Islands
Malaysia
Mexico
Mongolia
Myanmar
Nepal
Nigeria
Pakistan
Philippines
Poland
Romania
Russia
Solomon Islands
Tonga
Vietnam
Western Samoa
Yemen
Mean
13.7 (2.05)
0.9 (0.14)
11.6 (1.88)
Note. The average tar, nicotine, and CO yields (mg) for twenty-nine cigarette brands sold in developing
countries. Source: Calafat et al., 2004.
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A study that examined machine-smoked TSNA levels in cigarettes found differing
levels between exported U.S. cigarettes and cigarettes made locally in other countries
(Ashley et al., 2003). The study was conducted in two phases. Phase one examined the
TSNA content of Marlboro brand, full flavor cigarettes made in or exported to 21
countries and compared this to the popular cigarette brands made locally in these
countries. In 71% of the countries, Marlboro cigarettes had higher levels of TSNAs than
the local, non-Marlboro brands. Phase two was similar and it included fourteen
countries. The TSNA levels of Marlboro full flavor cigarettes made in or exported to
these countries were compared to the TSNA levels found in the popular, locally made,
full flavor cigarettes. In 85% of the countries, TSNA levels were higher in the Marlboro
brand cigarettes than in the locally made cigarettes. In developing countries, the highest
TSNA levels were found in Marlboro brands that were purchased in Bangladesh (1.9
pg/g

0.1 vs. 0.2 pglg & 0.02 local brand), Indonesia (1.9 pg/g k 0.2 vs. 0.4 pglg 2 0.03

local brand), and Kenya (1.8 pg/g +- 0.2 vs. 0.2 pg/g +: 0.02 local brand). The lowest
TSNA levels were found in cigarettes that were made in Kenya (0.2 pg/g + 0.02; Ashley
et al., 2003). Again, determining the actual TSNA exposure of smokers in these
countries requires clinical exposure studies. Clinical studies that examine carcinogen
exposure in smokers in developing countries may help to predict disease rates, and will
provide a baseline with which to compare efforts to reduce carcinogen levels in smokers
(i.e., harm reduction efforts).

CO levels that cigarettes in developing countries yield. Several studies have used
machine smoking methods to examine CO yield from cigarettes marketed in developing
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countries. For example, Mitacek et al. (1990) examined six brands of locally made Thai
cigarettes to determine their FTC CO yields and these yields were compared with the
yields of two U.S. brands. Results indicated that, with the exception of one local brand
(18.9 mglcig), the mean CO yield of locally made filtered brands (16.8 mglcig k 1.6) is
comparable to the mean yield of a U.S. filtered, full flavor brand (15.0 mglcig; Mitacek et
al., 1990). A similar study examined the IS0 CO yields of the five most popular brands
and two brands of recent popularity that are sold in Bahrain (Hamadeh et al., 1994). The
mean CO yield was 12.7 mglcig k 1.4, also similar to the CO yield of light brands sold in
the U.S. (Table I). In cigarettes from 29 developing countries, the mean CO yield was
11.6 mglcig k 1.9, also similar to U.S. light cigarette brand yield (see Tables 1 and 2;
Calafat et al., 2004). The CO yield of cigarettes from only one country (Philippines mean
= 17.0 mg) was substantially higher than U.S. brands. Though the CO yields of cigarette

brands in developing countries are comparable to those in developed countries, CO yield
may not predict smokers' CO exposure. As no clinical studies on CO exposure have
been completed in these countries, smokers' exposure to CO is unknown.
Nicotine levels that cigarettes in developing countries yield. Several studies have

used machine smoking methods to examine nicotine yields in cigarettes sold in
developing countries, though nicotine exposure is uncertain. For example, a study in
India examined nicotine yields (FTC method) in Indian cigarettes as compared to U.S.
cigarettes (Pakhale & Maru, 1988). Results indicated that Indian cigarettes had a higher
yield of nicotine (2.58 mg) than the U.S. cigarettes (1.72 mg). These higher yields of
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nicotine may lead to higher levels of nicotine dependence in smokers in this country
(Pakhale & Maru, 1988) which could lead to higher rates of tobacco-related disease.
Seftel(1979) found similar results when nicotine yields of cigarettes sold in
developing (South Africa, Malaysia) and developed countries (U.S., U.K.) were analyzed
using FTC methods. The range of nicotine yields in cigarettes sold in South Africa was
1.04-1.93 mg while the range in American cigarettes was lower, 0.6-1.64 mg.
Interestingly, the nicotine yield of one brand of cigarettes differed across countries: South
Africa (1.72 mg), England (1.4 mg), and Malaysia (2.45 mg; Seftel, 1979). These
nicotine levels are higher than those typically found in developed countries such as the
U.S. (Table I). However, different results were observed in a similar study (Calafat et
al., 2004). FTC machine-smoked nicotine yields were determined from cigarettes that
were made and sold locally in 35 countries and compared to the nicotine yields of
Marlboro brand cigarettes that were either made in the U.S. and exported to or
manufactured in these countries. The mean nicotine yields for local brands (0.9 mglcig +
0.2) were similar to mean yields for Marlboro cigarettes (0.9 mglcig 5 0.1; Calafat et al.,
2004).
These results highlight the need for more research on nicotine yields in order to
resolve the above conflicting results. Nicotine exposure studies are also needed as
previous studies have shown that yield does not represent actual exposure. Determining
nicotine yields and exposure in developing countries is a very important step in creating
cessation programs that are tailored to those smokers.
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Cigarettes in developing countries: summary of carcinogen, CO, and nicotine
yield and exposure. In contrast to developed countries, constituent yields of cigarettes in

developing countries are only recently being studied. Some studies suggest that, in
developing countries, the yield of some carcinogens (i.e., TSNAs; Ashley et al., 2003), is
higher than in developed countries, potentially increasing the risk of cancer in smokers
residing in these countries. However, several recent studies suggest that tar, CO, and
nicotine yields in developed and developing countries may be comparable (e.g., Calafat
et al., 2004; but see Mitacek et al., 1990 and Firat, 1996). TSNA, tar, and CO exposure
can lead to smoking-related morbidity and mortality (e-g., cancer and cardiovascular
disease). Unfortunately, no data are available to determine definitively if smokers in
developing countries are exposed to higher, lower, or similar levels of carcinogens, tar,
CO, andlor nicotine, relative to smokers in developed countries. Regarding disease rates,
some studies indicate that smoking-related mortality is actually lower in developing
countries (Ezzati & Lopez, 2003), although several factors must be considered when
interpreting this result. First, smoking prevalence has been increasing in developing
countries (especially among women) and decreasing in developed countries, a fact that
may not be reflected in mortality rates for several decades. Second, in developing
countries, non-tobacco related sources of carcinogens and CO may be more common than
in developed countries, thus rates of smoking attributable cancer and cardiovascular
disease may appear lower due to non-smoking attributable morbidity and mortality
(Ezzati & Lopez, 2003). Third, analyses of morbidity by region rather than country (i.e.,
as in Ezzati & Lopez, 2003) may obscure effects from countries where carcinogen and/or
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CO yield are high (e.g., Nepal; Philippines; Calafat et al., 2004). Thus, differences in
smoking related morbidity and mortality in developing countries, relative to developed
countries, may become more apparent in the future, especially as research and reporting
methods become more refined.
Clearly, exposure studies using smokers in developing countries are necessary for
understanding the levels of carcinogens, CO, and nicotine that they receive, and may help
to predict risk of cancer, cardiovascular disease, and addiction. In particular,
understanding nicotine dependence levels may be relevant to planning effective cessation
interventions in developing countries (Maziak et al., 2004). Thus, studying the smoke
constituent exposure of smokers who smoke cigarettes marketed in developing countries
is likely critical for understanding and reducing the impact of the global tobacco
epidemic.
Despite the need for this type of research, no studies regarding the toxicant
exposure of smokers in developing countries have been identified. Moreover, the puff
topography and ventilation blocking of smokers in these countries is unknown. Thus, an
important first step might be to examine the nicotine and CO exposure of smokers using
cigarettes marketed in developing countries under conditions that do not allow changes in
puff topography or blocking of filter ventilation holes. While not necessarily reflective of
actual exposure, data collected under these conditions, when used in conjunction with
machine smoke yield analysis, may provide a benchmark of CO and nicotine yield and
exposure with which to compare data from more naturalistic smoke toxicant exposure
studies.
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Statement of Hypothesis

The results of interest will be smokers' toxicant exposure measured by plasma
nicotine levels and breath carbon monoxide (CO), as well as cardiovascular and
subjective response (i.e. withdrawal effects) observed during the smoking sessions. The
predicted results obtained under conditions where puff topography is held constant and
ventilation hole blocking is not permitted are based on the following two hypotheses:
1. Relative to American full flavor and ultra light cigarettes with lower FTC nicotine and
CO yields, cigarettes from a developing country (Syria) that have higher FTC nicotine
and CO yields will expose smokers to a higher level of nicotine and CO.
2. Relative to American ultra light cigarettes that have lower nicotine and CO yields,
American full flavor cigarettes that have higher nicotine and CO yields will expose
smokers to higher levels of nicotine and CO.

Chapter 2
Method

This project involved two concurrent studies using methods that differed in only
one respect: the brand of developing country cigarettes used (i.e., Syrian Alharnraa
cigarettes were used in Study 1 and Syrian A1 Sham cigarettes were used in Study 2).
Because all other methods were identical across the two studies, one description is
provided below.
Selection of Subjects

A combined total of 21 and 19 male and female tobacco cigarette smokers completed
Studies 1 and 2, which involved a single session in which participants smoked one
Syrian, one U.S. full flavor, and one U.S. ultra light cigarette. More specifically, 17
males (3 non-white) and 4 females (1 non-white) completed Study 1 and 16 males (5
non-white) and 3 females (0 non-white) completed Study 2. For each three-condition
within-subject study, an n of 20 was sufficient in order to have an 80% chance of
detecting a medium effect size (i.e., f

- .35) assuming a large within-subject correlation

across repeated measures (r > SO; Barcikowski & Robey, 1985). ES is defined as the
standard deviation of standardized means and is expressed as f= [q2/(1-q2)]%where q2 is
equal to multiple R2, which is an index of the proportion of the variability explained by
the independent variable (Cohen, 1988). The within-subject correlation was expected to
be large based on previous acute studies of changes in nicotine and CO levels across
smoking episodes (i.e., Breland, Buchhalter, Evans, & Eissenberg, 2002a, b; Breland,
Acosta, & Eissenberg, 2003).
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Participants were recruited by word of mouth, IRB approved advertisements and
fliers. All study-related activities took place on Virginia Commonwealth University's
Medical Campus in the Clinical Behavioral Pharmacology Laboratory.
Participants were healthy, regular smokers between the ages of 18 and 50 (Study
1 mean = 29.1, SD = 11.0, Study 2 mean = 29.5, SD = 10.3). Specific inclusion criteria
were: 1) self-reported daily cigarette intake of at least ten cigarettes per day for the last
year (Study 1 mean = 20.2, SD = 3.8, Study 2 mean = 22.4, SD = 10.4); 2) expired air
sample containing

15 ppm CO (expired air was tested using non-invasive equipment

and took about 30 seconds) to confirm smoking status (Study 1 mean = 26.2, SD = 9.0,
Study 2 mean = 27.9, SD = 11.2. See Tables 3 and 4.); 3) usual cigarette brand that was
king sized, full flavor, and non-mentholated, so that comparisons could be made with the
two Syrian cigarette brands that were king-size, full flavor, and non-mentholated.
Exclusion criteria were 1) current pregnancy or breast feeding; 2) history of selfreported cardiovascular problems; 3) inability to respond to screening materials reliably;
4) inability to demonstrate controlled smoking parameters reliably (described below).
A total of 78 participants enrolled in Studies 1 and 2 and of those 78, 38 were
excluded due to ineligibility: six had low screening CO (< 15 ppm), one was over the age
limit of 50 years, thirteen smoked non-full flavor andlor non-king sized cigarettes, one
smoked for < 1 year, one quit smoking once enrolled, one failed to demonstrate control
over smoking parameters, and nine failed to return for the smoking session. The data of
six participants (four from Study 1 and 2 from Study 2) were excluded at the end of the
studies due to plasma nicotine levels that were inconsistent with 12 hours of abstinence
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despite having provided a CO breath sample that was below the 10 ppm cut off value.
Participants had a mean Fagerstrom score of 5.4 (SD=1.7) for Study 1 and 5.5
(SD=1.9, P > .05; n.s.) for Study 2 indicating a moderate nicotine dependence level in
both groups. The mean FTC yields for the tar, nicotine, and CO of participants own
brand of cigarettes are shown in Tables 5 and 6. Twenty participants reported full flavor
and one participant reported medium cigarettes as own brand in Study 1. All participants
in Study 2 reported full flavor as own brand. As medium cigarettes have similar FTC
reported levels of tar, nicotine, and CO to full flavor cigarettes and higher FTC levels
than light and ultra light cigarettes, the participant in Study 1 was not excluded.
Table 5
Mean FTC yields of the cigarettes examined in Study 1 and participants' own brand

Mean mglcig (SD)
Cigarette

Tar

Nicotine

CO

14.8 (1.1)

1.1 (0.1)

13.9 (0.5)

Marlboro Full Flavor

15.0

1.1

14.0

Marlboro Ultra Light

6.0

0.5

7 .O

Alharnraa*

23.1

1.4

15.3

Own brand

*FTCvalues obtained from independent analysis.
' ~ = 1 9for tar and for nicotine; N= 18 for CO.

Table 6
Mean FTC yields of the cigarettes examined in Study 2 and participants' own brand

Mean mglcig (SD)
Cigarette

Tar

Nicotine

CO

15.1 (1.1)

1.1 (0.1)

14.1 (0.2)

Marlboro Full Flavor

15.0

1.1

14.0

Marlboro Ultra Light

6.0

0.5

7.0

A1 Sham*

20.2

1.2

13.6

Own brand

*FTC values obtained from independent analysis.

' ~ = 1 8for CO.

Procedure

After a telephone screening interview, potentially eligible individuals provided
documented informed consent and completed an in-person screening. Eligible
individuals then completed a single practice session and, at least 24 hours later were
given an alternating assignment to one of the two studies. In each study, participants
completed a single evaluation session in which they completed three smoking bouts, each
separated by 90 min. In each bout they took 10,40 ml puffs (with a 30 second PI).
Bouts differed by the cigarette smoked (Syrian, U.S. full flavor, or U.S. Ultra light) and
order of cigarette presentation was determined by Latin square. Blood and CO were
sampled before and after each bout, as was self-reported withdrawal and direct effects of
cigarettes; heart rate (HR) was measured continuously (although not primary outcome
measures, subjective and HR effects were measured to compare the effects of Syrian and
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U.S. cigarettes). In addition, puff topography was monitored and measured during each
bout.
Telephone screening. Potential participants were screened over the telephone

using questionnaires to assess self-reports of current health and smoking status
(Appendix A). The questions were related to participants' demographics, physical and
mental health, smoking history, drug history (over-the-counter, prescription, and illicit
drug use), and menstrual cycle information (women only). Participants' nicotine
dependence (CAGE questionnaire for smoking, Lairson et al., 1992; Fagerstrom Test for
Nicotine Dependence, Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991), alcohol use
(CAGE questionnaire for alcoholism, Ewing, 1984), and marijuana use (questions are
similar to the CAGE questionnaire for smoking/nicotine dependence) were also assessed
(Appendix A). Individuals deemed potentially eligible based on their telephone screen
results were invited to come to the laboratory to learn more about the study, provide
informed consent, and to complete an in-person screening and training session.
Informed consent and in-person screening. The informed consent and in-person

screening began with the research assistant reading the IRB approved consent form aloud
to the participant (Appendix B). This method was used to be certain that the material in
the consent form was presented to the potential participant, and also to address any
questions or concerns regarding study procedures, risks, and benefits, as well as research
participant rights. Participants had to provide voluntary, written, informed consent in
order to proceed with the study.
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Following the completion of the consent process, participants were asked to
provide information about their demographics and smoking behavior using a variety of
questionnaires (Appendix C). Many of the in-person screening questionnaires were
identical or similar to those used in the telephone screen. This redundancy allowed an
assessment of individuals' ability to report information reliably (as noted, unreliable
individuals were excluded from participation). Data collected during the in-person screen
were used to determine eligibility.
After completing in-person screening and verification of reliability, eligible
individuals provided an expired air CO sample to verify current smoking status. Breath
CO measurement is a non-invasive, reliable index of blood CO levels (Rawbone et al.,
1976; Wald, Idle, Boreham, & Bailey, 1981; Guyatt et al., 1988). If breath CO levels did
not reach or exceed 15 ppm (indication of recent smoking), the practice session was
rescheduled. Once the CO criterion was met, participants were trained to smoke using
the protocol-specific, controlled smoking parameters, as described below.
Practice session. Participants who qualified for the study based on the telephone
and in-person screening process had to complete a practice session. The purpose of the
practice session was twofold, as it allowed participants to: 1) familiarize themselves with
all questionnaires used in the evaluation session, and 2) demonstrate their ability to
control their smoking behavior.
Eligible participants began the practice session by reviewing and responding to
the computerized questionnaires that were used to assess withdrawal and the direct
effects of cigarettes during the evaluation session. This procedure was used to address
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any issues regarding the questionnaires and to ensure participant familiarity with the
scales and computer equipment. Once the questionnaires were completed and all issues
addressed, the equipment and procedures used to control smoking (i.e., puff topography
system) were introduced.
First, the research assistant activated the computerized "directed smoking"
module of the laboratory software (CReSS; Plowshare Technologies, Baltimore, MD)
and then inserted an unlit cigarette into the mouthpiece that was connected to the
topography hardware (see below for description of this software and equipment).
Participants were instructed to hold either the mouthpiece or the black tubing attached to
the mouthpiece without touching the cigarette. The participants then observed the
directed smoking screen on the computer, which provided the visual and auditory
feedback that helped participants control their own smoking behavior (puff volume and
inter-puff-interval, or P I ) . Participants were instructed on how to make use of the
feedback (e.g., how large their puffs should be, what the auditory cues mean, how long to
wait between puffs, etc.). Specifically, participants were instructed to inhale from the
cigarette until a warning beep sounded (at 35 ml), to stop inhaling when they reached the
target puff volume as displayed on the screen (40 ml; values within the range of 37 to 43
ml were acceptable), and to wait for the 30 sec timer to count down to zero (and for the
associated auditory cue) before taking their next puff. When the participants were
comfortable with the procedure, they were instructed to attempt ten consecutive puffs of
the target puff volume. The research assistant kept track of the number of puffs,
restarting the count from one if the puff volume was not within the acceptable range. Ten
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consecutive puffs within the acceptable range were required before the practice session
was terminated and an evaluation session was scheduled. Once the ten puff criterion was
reached, participants were paid $30 for their time and scheduled for the evaluation
session.
Evaluation session. Prior to the onset of the evaluation session, each participant

who had completed the practice session was assigned to a particular study (i.e.,
examining the Syrian cigarette brand "A1 Sham" or "Alhamraa") and then a particular
Latin-square order of cigarette presentation within a session (e.g., Syrian, U.S. full flavor,
U.S. ultra light). The Latin square ordering was used to minimize order effects. Thus,
each study used a within-subject design to compare a Syrian brand with a U.S. brand and
U.S. brands with each other.
The approximately 4-hour evaluation session had to be preceded by at least eight
hours of cigarette abstinence (verified with expired air CO < 10 ppm; e.g., Buchhalter,
Schrinel, & Eissenberg, 2001) and had to be separated from the practice session by at
least 24 hours. Abstinence was required primarily so that plasma nicotine and expired air
CO levels at baseline would be minimal, so that smoking-induced changes in these
variables could be measured.
Once participants met the CO criterion, a research nurse inserted a heparinized
catheter into a forearm vein to accommodate repeated blood sampling. A catheter was
used because repeated venipuncture can be aversive and could have altered some
outcome measures (e.g., HR). Once the catheter was inserted, continuous HR monitoring
commenced and continued throughout the session. During the first 20 min of the session,
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participants practiced the smoking procedure (using an unlit cigarette) so that they could
re-establish control over their smoking behavior. HR data collected during the last five
min of this practice period was used as a measure of baseline HR (see data analysis,
below). At the end of the 20 min period, a 10 ml blood sample was drawn, breath CO
was measured, and participants responded to computerized subjective questionnaires
assessing tobaccolnicotine withdrawal (the Questionnaire of Smoking Urges, Tiffany &
Drobes, 1991; and the Hughes-Hatsukami visual analog scales, Hughes & Hatsukami,
1986) and the direct effects of smoking (adapted from Pickworth, Burker, &
Henningfield, 1994). When the questionnaires were completed, a lit cigarette,
corresponding to the appropriate grouplcondition, was inserted into the mouthpiece by
the research assistant. The participant was instructed to begin the smoking portion of the
bout by taking the first 40 ml puff and attending to the visual and auditory cues that
indicated when the 30 sec P I had been reached. When participants completed their fifth
puff of the bout, a new cigarette of the same brand was lit and inserted into the
mouthpiece; two cigarettes of each brand were used (five puffs from each) to control for
the different burn times of the cigarette brands so that no cigarette burned to the end
before a participant finished their tenth puff. Once participants had completed their tenth
puff, another 10 ml of blood were drawn, participants responded again to the
questionnaires, and, exactly five min after the tenth puff, expired air CO was measured (a
five min delay ensured that the reading accurately reflected blood CO levels and not
residual smoke from the mouth). This entire procedure (blood, CO, questionnaires, ten,
40-ml puffs with a 30 sec IPI, blood, questionnaires, five min post-puff CO) was repeated
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every 90 min until each participant had taken ten puffs from all three brands used in that
session. The inter-bout-interval of 90 min was chosen to reduce the influence that a first
or second smoking bout would have on the second or third bout. However, because
nicotine's half-life is 60- 120 min (Ahijevych, 1998; Benowitz, 1996; Zevin, Gourlay, &
Benowitz, 1998), and because CO's half-life is 240-300 min (Stewart, 1975) residual
nicotine and CO were detectable after the first smoking bout. After the last CO measure
of the last bout, the catheter was removed, HR recording discontinued, and participants
were paid $150 for the time spent in the laboratory. Thus, with the practice session, each
participant earned $180 for completing this study successfully.
Materials

The two brands of Syrian produced cigarettes used were Alhamraa and A1 Sham.
These brands were chosen because they are the most popular brands of Syrian produced
cigarettes used by smokers in Syria (Dr. Wasim Maziak, personal communication).
According to analyses performed by an independent laboratory, the mean (SD) FTC
yields for Alhamraa cigarettes for tar are 23.1 (0.8) mg, for nicotine are 1.4 (0.04) mg,
and for CO are 15.3 (0.6) mg (see Table 5). For A1 Sham cigarettes, the mean (SD) FTC
yields for tar are 20.2 (0.7) mg, for nicotine are 1.2 (0.06) mg, and for CO are 13.6 (0.4)
mg (see Table 6).
Marlboro full flavor and ultra light cigarettes served as the U.S. cigarettes to
which the Syrian brands were compared. Marlboro full flavor cigarettes are one of the
most popular brands among full flavor smokers in the U.S. (CDC, 2004). The mean (SD)
FTC yields for Marlboro full flavor cigarettes for tar are 15 (1.5) mg, for nicotine are 1.1
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(0.15) mg, and for CO are 14 (1.5) mg. For Marlboro ultra light cigarettes, the mean
(SD) FTC yields for tar are 6 (1.5) mg, for nicotine are 0.5 (0.12) mg, and for CO are 7
(1.5) mg (FTC, 2000).
The FTC classifies domestic cigarettes into three categories depending on their
content of 'tar' and nicotine: typical regular (full flavor), typical "light", and typical
"ultra light" (see Table 1). Full flavor cigarettes contain 15.63 mg tar and 1.15 mg
nicotine. "Ultra light" cigarettes contain 5.14 mg tar and 0.47 mg nicotine (FTC, 2000).
Opaque tape was used to conceal any identifying labels on all cigarettes; the tape
was positioned so that it did not block any filter ventilation holes.
Primary Outcome Measures

Primary outcome measures included plasma nicotine and expired air CO level.
Plasma nicotine level. Blood samples were centrifuged immediately and plasma

was stored at -70° C for later analysis of nicotine concentration using high performance
liquid chromatography and mass spectrometry (J. R. James, VCU Department of
Pharmaceutics, personal communication, March 5, 2004). This assay has a limit of
quantitation (LOQ; minimum detectable concentration) of 2.0 nglml.
Expired air CO. Expired air CO was measured at screening and before and 5 min

after participants took ten puffs from each cigarette, using a BreathCO monitor
(Vitalograph, Lenexa, KS).
Secondary Outcome Measures

Secondary outcome measures included cardiovascular response (i.e., heart rate),
puff topography, direct effects of smoking, and subjective measures of withdrawal.
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Hear rate. During each session, HR was measured every 20 sec by non-invasive

computerized equipment (Noninvasive Patient Monitor model 507E, Criticare Systems,
Waukesha, WI).
Puff topography measures. Participants' puff volume, number and P I were

monitored and measured using a desktop computerized puff topography measurement
system that also administered all questionnaires and stored all physiological data (CReSS,
Plowshare Technologies, Baltimore MD). The topography system provided feedback to
help participants monitor and control puff volume and IPI. This system consisted of a
mouthpiece, tubing, transducerlarnplifier, and computer; cigarettes were smoked through
the mouthpiece, and pressure changes created by an inhalation were transferred to the
computer via the transducerlamplifier while smoking occurred. Puff topography has been
found to be a valid and reliable index of smoking behavior (Lee, Malson, Waters,
Moolchan, & Pickworth, 2003).
This computerized puff topography system was used to train and maintain
participants' puffing behavior. During training and evaluation sessions the screen
displayed a target puff volume as well as counters for the current puff volume and P I .
At the beginning of the evaluation session, participants were handed a mouthpiece with a
lit cigarette inside, and the screen flashed "Puff when ready." As subjects inhaled, the
current puff volume counter increased. A warning tone sounded when the current
volume approached the target volume (at 35 ml), and the counter displayed the actual
puff volume; thus both visual and auditory feedback were given. Once the computer
determined that the puff was terminated (as measured by a lack of pressure in the
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mouthpiece), the computer displayed the message "Puff again when you hear the tone";
the P I counter counted down. When the P I counter reached zero, a final tone sounded,
the screen flashed "Please puff now" and the process was repeated. Actual puff
topography data (volume, P I ) were recorded for later analysis and reporting. This
procedure is a modified version of one used previously to control smoking behavior (e.g.,
Azorlosa, Heishman, Stitzer, & Mahaffey, 1992). In addition to the computerized
measures, a research assistant recorded the puff numbers manually for reliability.
Subjective measures of the direct eflects of smoking and withdrawal. In addition

to physiological responses, participants responded to computerized questionnaires during
the smoking session, prior to and after smoking from each brand of cigarette.
Participants responded to visual analog scales (VAS) that assessed the direct effects of
smoking. In addition, there were two questionnaires that measured subjective tobacco
withdrawal: a visual analog scale derived from tobacco/nicotine withdrawal symptoms
described by Hughes & Hatsukami (1986), and the Questionnaire of Smoking Urges
(QSU; Tiffany & Drobes, 1991). Each measure is described in detail below.
The Direct Effects of Smoking scale is comprised of thirteen VAS items
(Appendix F). A VAS item is presented as a word or a phrase centered above a
horizontal line and anchored on the left with "not at all" and on the right with
"extremely". Using a computer mouse, subjects responded to each item by moving a
cursor to place a vertical mark at any point on the horizontal line. Subjects could adjust
the placement of the mark. Scores for each question were assessed as the distance of the
vertical mark from the left anchor and calculated as a percentage of the length of the
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horizontal line. The thirteen items in this scale were: "Was the cigarette satisfying?,"
"Was the cigarette pleasant?," "Did the cigarette taste good?," "Did the cigarette taste
bad?," "Did the cigarette make you dizzy?," "Did the cigarette calm you down?," "Did
the cigarette make you feel confused?," "Did the cigarette help you concentrate?," "Did
the cigarette make you feel more awake?," "Did the cigarette reduce your hunger for
food?," "Did the cigarette make you sick?," "Did the cigarette make you sleepy?,"
"Would you like to smoke another cigarette right now?" Participants responded to each
of the items by using the mouse to place a mark on a horizontal line that was anchored
between "Not at all" and "Extremely." This scale was adapted from VASs that have been
used previously to assess various characteristics of cigarettes (e.g., Pickworth et al.,
1994).
The Hughes & Hatsukami (1986) questionnaire consists of thirteen VAS items
(Appendix D). Past studies completed in this lab have used only the following eleven
items: "Urges to smoke", "Irritability/frustratiodanger", "Anxious", "Difficulty
concentrating", "Restlessness", "Hunger", "Impatient", "Craving a cigarettelnicotine",
"Drowsiness", "Depressiodfeeling blue", and "Desire for sweets". The items of
"Insornnia/increased sleep" and "Increased eating" are not presented to participants
because they do not sleep or eat in the laboratory setting. This questionnaire is sensitive
to deprivation-induced withdrawal and cigarette-induced withdrawal suppression
(Buchhalter et al., 2001; Breland et al., 2002a, b).
The QSU (Tiffany & Drobes, 1991) is an empirically validated scale made up of
32 items related to smoking (e.g., "Smoking would make me feel very good right now",
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"I have an urge for a cigarette") (Appendix E). Subjects rated each item on a 7-point

scale ranging from 1 (Strongly disagree) to 7 (Strongly agree). Using the computer
mouse, subjects placed a mark in the appropriate box for a score ranging from 0 through

6. Items from the QSU were collapsed into two factors that have been previously defined
by factor analysis: Factor 1 is related to intention to smoke and Factor 2 is related to
anticipation of relief from withdrawal. This questionnaire is sensitive to deprivationinduced withdrawal and cigarette-induced withdrawal suppression (Buchhalter et al.,
2001; Breland et al., 2002a, b).
Participant Safety and Rights

In this study, the risks smokers incurred were minimal relative to the risks they

encountered daily as smokers. Participants may have suffered mild discomfort after eight
or more hours of cigarettes abstinence. However, this mild discomfort was not medically
dangerous. There were also minimal risks associated with blood sampling, which were
reduced by having a trained nursing professional who used aseptic procedures. Finally,
there was a very small risk of an unintended breach of confidentiality.
Trained staff ensured that the rights of the participants were protected at all times
during study participation. Medical risks were minimized by careful monitoring
throughout each experimental session, a nurse who was present during each session, and
aseptic blood sampling procedures using only sterile, disposable equipment. Noninvasive computerized monitoring equipment allowed minute-by-minute, real-time
monitoring of participants' HR. Research personnel were trained to call for medical
assistance if HR exceeded 120 bpm. Emergency medical coverage was available via the
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emergency room that was ?hblock away from the laboratory. Confidentiality was
ensured by referring to participants only by a code number and initials. All subject files
are kept in a locked cabinet that resides in a locked laboratory. Potential participants
were advised of these risks and the steps taken to minimize them, and were also advised
of their right to refuse to participate or terminate their participation at any time during the
study.
Data Preparation and Analysis

All data where pre- and post-smoking values were collected (i.e., every measure
except topography and direct effects) were processed to form post-smoking difference
scores. For each cigarette smoked, pre-smoking plasma nicotine levels in nglml (as
determined through GCIMS) were subtracted from post-smoking nicotine levels, to form
a "nicotine boost" difference score. Pre- and post-CO levels were processed identically,
to form a "CO boost" difference score. Subjective assessments of withdrawal (HughesHatsukami VAS and Tiffany-Drobes QSU) were averaged to determine mean pre- and
post-smoking scores for each item. The Tiffany-Drobes QSU data were then placed into
a set formula to determine Factor 1 and Factor 2 scores. Subjective assessments of direct
effects of cigarettes were post-cigarette only and so were averaged into mean postsmoking scores.

HR for each participant was measured continuously throughout the entire
evaluation session. Data from the session were taken from the 5 min periods before and
after smoking each of the three cigarettes for each participant for analysis. These data
were used to form a "HR boost" difference score.
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Smoking topography data were collected during the smoking of each of the three
cigarettes during the evaluation session. As in previous work (i.e., Breland et al., 2001;
Baldinger, Hasenfratz, & Battig, 1995), topography data was processed such that puffs
that were separated by less than 250 ms were combined and, after that combination, any
puffs smaller than 5 ml were deleted. These data were then analyzed using one-sample ttests with set values for each measure (10 for puff number, 30 for P I , and 40 for puff
volume) to determine the consistency with which the directed smoking rules were
followed (i.e., puff volume = 40 ml; P I = 30 sec).
Data for all measures (except topography) were then entered in a single factor
within-subjects analysis of variance (ANOVA), with three levels (cigarette: Syrian, U.S.
full flavor, and U.S. ultra light). Huynh-Feldt corrections were used to adjust for any
violations of the sphericity assumption. The sphericity assumption states that the
variance of the difference scores in the levels of a within-subjects design is equal across
the levels (Grimrn and Yarnold, 2000). The sphericity assumption is made when
statistical significance is assigned to an F-value derived from an ANOVA. Violating this
assumption and leaving it uncorrected increases the likelihood of making a Type I error
(falsely rejecting the null hypothesis) because the ANOVA underestimates the amount of
variance associated with each variable. Therefore, in order to control for violations of
this assumption, the Huynh-Feldt correction adjusts the degrees of freedom associated
with the critical F-value such that this value will be more conservative (higher). As a
consequence of increasing the critical F-value, the likelihood of making a Type I error is
no longer inflated by the violation of the sphericity assumption.
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After any significant ANOVA result, the post-hoc analysis, Tukey's Honestly
Significant Difference [HSD], was used to explore possible differences among the means.
Tukey's HSD is a conservative post-hoc test designed to compare all possible pairs of
means while maintaining the Type 1 error rate (Hurlburt, 1998). The experimentwise
error rate can increase with each pairwise comparison that is made and Tukey's HSD
prevents this error rate increase. The mean square error terms for the overall interaction
were used to conduct Tukey HSD post hoc tests. Finally, an alpha level of P c .05 was
used to determine significance in all of the above analyses and Tukey's HSD was used to
explore differences after a significant ANOVA.

Chapter 3
Results

The two studies reported here were designed to examine how two brands of
Syrian cigarettes (Study 1 = Alhamraa; Study 2 = A1 Sham) influenced smokers' toxicant
exposure (plasma nicotine; expired air CO) and cardiovascular and silbjective response
(i.e. withdrawal effects) under conditions where puff topography was held constant and
ventilation hole blocking was not permitted. Results from the two studies are described
below.
Primary Outcome Measures: Study 1 (Alhamraa)

Results of the statistical analysis of primary outcome measures are presented in
Table 7 and are discussed below.
Nicotine boost. As Table 7 shows, for nicotine boost (post smoking plasma

nicotine level minus pre smoking plasma nicotine level), a significant main effect of
cigarette was observed. The data are displayed in Figure 1. As can be seen in the figure,
on average, U.S. ultra light cigarettes produced less nicotine exposure (mean = 3.9 ng/ml,
SD = 2.9) relative to U.S. full flavor cigarettes (mean = 10.4 ng/ml, SD = 9.8; P < .05,
Tukey's HSD), though no significant difference was observed between U.S. full flavor
and Alhamraa cigarettes (mean = 7.3 nglml; SD = 8.3; difference between means n.s.;
Tukey's HSD).
CO boost. Also shown in Table 7, a significant main effect of cigarette was

observed for CO boost (post smoking expired air CO minus pre smoking expired air CO).
The data are displayed in Figure 1. As can be seen in the figure, on average, U.S. ultra
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light cigarettes produced less CO exposure (mean = 2.7 ppm, SD = 1.8) relative to U.S.
full flavor cigarettes (mean = 5.3 ppm, SD = 2.9; P < .05, Tukey's HSD) and Alhamraa
cigarettes (mean = 4.5 ppm; SD = 3.2; P < .05; Tukey's HSD), though no significant
difference was observed between U.S. full flavor and Alhamraa cigarettes (difference
between means n.s.; Tukey's HSD).
Secondary Outcome Measures

Results of the statistical analysis of secondary outcome measures are presented in
Tables 7 and are discussed below.
Heart rate. HR was averaged for the 5 minutes before and after smoking, and the

resulting post-smoking means were subtracted from pre-smoking means and reported as

HR boost. As Table 7 shows, there was a significant main effect of cigarette on this
outcome measure, with U.S. ultra light cigarettes producing, on average, less tachycardia
(mean = 9.0 bpm, SD = 4.0) relative to U.S. full flavor cigarettes (mean = 12.1 bpm, SD
= 5.5; P < .05, Tukey's HSD). U.S. full flavor cigarettes produced, on average, more

tachycardia relative to Alhamraa cigarettes (mean = 9.7 bpm; SD = 3.7; P < .05, Tukey's
HSD. See Figure 1).

Figure 1

1

Ultra light
Full flavor
ElAlhamraa

Plasma nicotine (nglml)

Expired air CO (ppm)

Heart rate (bpm)

Mean plasma nicotine, expired air CO, and heart rate boost (post-cigarette minus pre-cigarettes values) + 1 SEM for 21 participants who smoked one
American ultra light (Marlboro), one American full flavor (Marlboro), and one Syrian (Alharnraa) cigarette at 90 min intervals in a 4 hour session.
Asterisks (*) indicate a significant difference relative to American full flavor on that outcome measure for that cigarette and a cross (t)indicates a
significant difference from American ultra light on that outcome measure for that cigarette (P < .05; Tukey's HSD).
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PufStopography. Topography data were analyzed to determine how well

participants followed the directed smoking procedures across the three cigarette
conditions. While there was some variability on all topography measures, a significant
main effect was observed for puff volume only (see Table 7). On this measure, mean
puff volume for the U.S. full flavor cigarettes (mean = 37.8 ml, SD = 5.1) was somewhat
smaller than for either the U.S. ultra light (mean = 40.4 ml, SD = 4.0) or Alhamraa
cigarettes (mean = 40.5 ml, SD = 4.5; all differences between means n.s.; Tukey's HSD).
Importantly, all means were within the +/- 3 ml limits allowable in the procedure.
Subjective measures of the direct efSects of smoking and withdrawal. For the

direct effects VAS measures significant main effects were observed for VAS items
assessing "Was the cigarette pleasant?," "Did the cigarette taste good?," "Did the
cigarette taste bad?"; an additional item ("Was the cigarette satisfying?") nearly attained
conventional levels of significance (i.e., P < .08; see Table 7). Results indicated that, on
these measures, participants indicated that smoking U.S. full flavor cigarettes were more
pleasurable and less aversive than smoking either U.S. ultra light or Alhamraa cigarettes.
For example, for "Was the cigarette pleasant?," mean values for the U.S. full flavor were
71.6 (SD = 23.1) compared to 52.8 for Alhamraa cigarettes (SD = 27.5; P < .05; Tukey's
HSD) though no significant difference was found between U.S. full flavor and U.S. ultra
light cigarettes (mean = 54.8, SD = 25.6; P <.05; difference between means n.s.; Tukey's
HSD). Also, for "Did the cigarette taste good?," mean values for U.S. full flavor
cigarettes were 72.0 (SD = 21.5) compared to 48.9 for U.S. ultra light (SD = 26.6; P <
.05, Tukey's HSD) and 47.4 for Alhamraa cigarettes (SD = 28.6; P < .05, Tukey's HSD).
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On the other hand, for "Did the cigarette taste bad?," mean values for U.S. full flavor
cigarettes were 20.3 (SD = 16.1) compared to 36.9 for U.S. ultra light (SD = 28.5) and
37.6 for Alharnraa cigarettes (SD = 29.0; P < .05; all differences between means n.s.;
Tukey's HSD).
For the Hughes-Hatsukami withdrawal VAS, administered before and after each
cigarette, significant time by cigarette interactions were observed for three items: "Urges
to smoke," "Irritability/Frustration/Anger,"and "Restlessness" (See Table 8). Table 8
provides summary statistics for these measures and, for "Urges to smoke" shows that presmoking levels were similar across the three cigarettes, but that U.S. full flavor cigarettes
suppressed urges more effectively than the other two brands (i.e., mean post-smoking
scores for U.S. full flavor cigarettes were significantly lower than for U.S. ultra light or
Alhamraa cigarettes; P < .05; Tukey's HSD). A different pattern of results was observed
for "Irritability/Frustration/Anger," where pre- and post-smoking scores were
significantly different only for U.S. ultra light cigarettes (P < .05; Tukey's HSD). Similar
results were seen for "Restlessness" where a significant difference between pre- and postsmoking scores in the U.S. ultra light cigarette condition seems to be the source of this
interaction (P< .05, Tukey's HSD; see Table 8).
A significant main effect of time was observed for almost every HughesHatsukami item (see Table 8). Inspection of the data showed that scores, collapsed
across cigarette, were high before smoking and significantly lower after smoking. For
example, for "Craving a cigarette/Nicotine" (the item with the highest F value, see Table
8), the mean pre-smoking score was 80.5 (SD = 18.0) and post smoking score was 44.4
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(SD = 29.6; P < ,05, Tukey's HSD). A similar pattern was observed on every measure
with a significant time by cigarette interaction.
A significant main effect of cigarette was observed for "Craving a
cigarette/Nicotine". Collapsed across time, mean scores were 56.2 for U.S. full flavor
(SD = 3 1.1), 68.9 for U.S. ultra light (SD = 20.8), and 62,3 for Alharnraa cigarettes (SD =
31.4; P < .05; all differences between means n.s.; Tukey's HSD).
For both factors of the QSU, a significant main effect of time was observed.
Inspection of the data showed that scores, collapsed across cigarette, were high before
smoking and significantly lower after smoking. For example, for Factor 2, (the factor
with the higher F value, see Table 8), the mean pre-smoking score was 3 1.0 (SD = 14.1)
and post smoking score was 23.6 (SD = 14.3; P < .05, Tukey's HSD).

Table 7
Mean physiological boost scores, topography values, and direct effect scores of Study 1

Mean (SD)

Nicotine boost
CO boost
Heart Rate boost?
Topography
Puff Number
Inter-puff-interval
Puff Volume

F

P

Ultra Light

Full Flavor

Alharnraa

8.0
10.1
5.4

<.05
<.001
<.01

3.9 (2.9)"
2.7 (1.8)"
9.0 (4.0)"

10.4 (9.8)
5.3 (2.9)
12.1 (5.5)

7.3 (8.3)
4.5 (3.2)
9.7 (3.7)"

10.3 (0.5)
31.9(2.6)
40.4 (4.0)

10.4 (0.8)
30.9(2.4)
37.8 (5.1)

10.5 (1.5)
31.6(2.8)
40.5 (4.5)

~ 1 . 0 ns
ns
<l.O
3.9
c.05

Direct Effects
Satisfy
Pleasant
Good taste
Bad taste
Dizzy
Calm
Confused
Concentrate
Awake
Less hunger
Sick
Sleepy
Another cig
f N=20.
"Indicates significant difference from U.S. full flavor.

Table 8
Mean scores of withdrawal and cravingfor Study 1
Mean (SD)
Time
Withdrawal

F

Cigarette
F
P

P

Hughes Hatsukami items
Urges to smoke
Irr/Frus/Ang
Anxious
Difftculty conc
Restlessness
Hunger
Impatient
Craving a cig/Nic
Drowsiness
DepReel blue
Desire for sweets
Tiffany Drobes QSU
Factor I
Factor 2
--

-

-

N=2 1
*Indicates significant difference from U.S. full flavor.

Time x Cigarette
F
P

Ultra Light
Pre
Post

Full Flavor
Pre
Post

Alhamraa
Pre
Post
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Primary Outcome Measures: Study 2 (A1 Sham)

Results of the statistical analysis of primary outcome measures are presented in
Table 9 and are discussed below.
Nicotine boost. As Table 9 shows, for nicotine boost, a significant main effect of

cigarette was observed. The data are displayed in Figure 2. As can be seen in the figure,
on average, U.S. ultra light (mean = 4.0 ng/ml, SD=3.7) and A1 Sham cigarettes (mean =
2.4 ng/ml; SD = 4.2) produced less nicotine exposure relative to U.S. full flavor cigarettes
(mean = 11.3 nglml, SD=7.1, P < .05, Tukey's HSD). No significant difference was
observed between U.S. ultra light and A1 Sham cigarettes (difference between means n.s.;
Tukey' s HSD).
CO boost. Also shown in Table 9, a significant main effect of cigarette was

observed for CO boost. The data are displayed in Figure 2. As can be seen in the figure,
on average, U.S. ultra light (mean = 2.4 ppm, SD = 1.3) and A1 Sham cigarettes (mean =
2.8 ppm; SD = 1.3) produced less CO exposure relative to U.S. full flavor cigarettes
(mean = 5.3 ppm, SD = 2.3; P < .05; Tukey's HSD). No significant difference was
observed between U.S. ultra light and A1 Sham cigarettes (difference between means n.s.;
Tukey's HSD).
Secondary Outcome Measures

Results of the statistical analysis of secondary outcome measures are presented in
Tables 9 and 10 and are discussed below.
Heart rate. As Table 9 shows, there was a significant main effect of cigarette on

this outcome measure, with U.S. ultra light (mean = 7.8 bpm, SD = 5.3) and A1 Sham
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cigarettes (mean = 6.6 bpm; SD = 4.4) producing, on average, less tachycardia relative to
U.S. full flavor cigarettes (mean = 14.5 bpm, SD = 7.2; P c .05, Tukey's HSD). No
significant difference was observed between U.S. ultra light and A1 Sham cigarettes
(difference between means n.s.; Tukey' s HSD).

Figure 2

Ultra light
F u l l flavor
15 -1

Al Sham

Plasma nicotine (nglml)

Expired air CO (ppm)

Heart rate (bpm)

Mean plasma nicotine, expired air CO, and heart rate boost (post-cigarette minus pre-cigarettes values) + 1 SEM for 19 participants who smoked one
American ultra light (Marlboro), one American full flavor (Marlboro), and one Syrian (A1 Sham) cigarette at 90 min intervals in a 4 hour session.
Asterisks (*) indicate a significant difference relative to American full flavor on that outcome measure for that cigarette (P < .05; Tukey's HSD).
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PufStopography. While there was some variability on all topography measures, a
significant main effect was observed for puff volume only (see Table 9). On this
measure, mean puff volume for U.S. full flavor cigarettes (38.6 ml; SD = 5.3) was
somewhat smaller for the U.S. ultra light (mean = 41.3 ml, SD = 3.8; difference between
means n.s.; Tukey's HSD) and A1 Sham cigarettes (mean = 42.2 ml, SD = 2.9; P < .05;
Tukey's HSD). Importantly, though participants' average puff volume was significantly
smaller when smoking U.S. full flavor cigarettes relative to A1 Sham cigarettes, all means
were within the +I-3 ml limits allowable in the procedure.
Subjective measures of the direct efSects of smoking and withdrawal. For the

direct effects VAS measures, significant main effects were observed for VAS items
assessing "Did the cigarette make you dizzy?," "Did the cigarette make you sick?"; two
additional items ("Did the cigarette calm you down?," "Did the cigarette make you feel
confused?") nearly attained conventional levels of significance (i.e., P < .lo; see Table 9).
Results indicated that, on these measures, participants indicated that smoking U.S. full
flavor cigarettes made them feel more dizzy and sick than smoking either U.S. ultra light
or A1 Sham cigarettes. For example, for "Did the cigarette make you dizzy?," mean
values for U.S. full flavor cigarettes were 42.4 (SD = 3 1.9) compared to 5.8 for U.S. ultra
light (SD = 11.4; P < .05, Tukey's HSD) and 6.4 for A1 Sham cigarettes (SD = 15.5; P <
.05, Tukey's HSD). Similarly, for "Did the cigarette make you sick?," mean values for
U.S. full flavor cigarettes were 15.6 (SD = 24.9) compared to 4.1 for U.S. ultra light (SD
= 7.6; P < .05, Tukey's HSD) and 3.7 for A1 Sham cigarettes (SD = 6.9; P < .05, Tukey's

HSD).
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For the Hughes-Hatsukami withdrawal VAS, administered before and after each
cigarette, significant time by cigarette interactions were observed for one item: "Urges to
smoke," and one additional item ("Hunger") nearly attained conventional levels of
significance (i.e., P < .lo; see Table 10). Table 10 provides summary statistics for these
measures and, for "Urges to smoke" shows that pre-smoking levels were similar across
the three cigarettes, but that both U.S. full flavor and ultra light cigarettes suppressed
urges more effectively than A1 Sham cigarettes (i.e., mean post-smoking scores for U.S.
full flavor and ultra light cigarettes were significantly lower than A1 Sham cigarettes; P <
.05; Tukey's HSD). A different pattern of results was observed for "Craving a
cigaretteINicotine," where post-smoking scores were lower for all cigarettes with no
difference between the brands (See Table 10). Finally, for "Desire for sweets," there was
a main effect of cigarette with the U.S. ultra light cigarettes showing the lowest score (all
differences between means n.s.; Tukey's HSD).
A significant main effect of time was observed for only two Hughes-Hatsukami
items (see Table 10). Inspection of the data showed that scores, collapsed across
cigarette, were high before smoking and significantly lower after smoking. For example,
for "Craving a cigarette/Nicotine" (the item with the highest F value, see Table lo), the
mean pre-smoking score was 64.9 (SD = 28.2) and post smoking score was 40.0 (SD =
30.2; P < .05, Tukey's HSD). For "Urges to smoke," the mean pre-smoking score was
67.5 (SD = 28.7) and post smoking score was 39.9 (SD = 31.6; P < .05; Tukey's HSD).
A similar pattern was observed on "Urges to smoke" which had a significant time by
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cigarette interaction for the U.S. cigarettes (P < .05; Tukey's HSD) but not for A1 Sham
cigarettes (difference between means n.s.; Tukey's HSD).
A significant main effect of cigarette was observed for "Desire for sweets."
Collapsed across time, mean scores were 16.6 for U.S. full flavor (SD = 29.4), 21.5 for
U.S. ultra light (SD = 30.0), and 27.8 for A1 Sham cigarettes (SD = 33.0; all differences
between means n.s.; Tukey's HSD).
For both factors of the QSU, a significant main effect of time was observed.
Inspection of the data showed that scores, collapsed across cigarette, were high before
smoking and significantly lower after smoking. For example, for Factor 1, (the factor
with the higher F value, see Table lo), the mean pre-smoking score was 70.0 (SD = 18.7)
and post smoking score was 57.2 (SD = 23.9; P c .05, Tukey's HSD).

Table 9
Mean physiological boost scores, topography values, and direct effect scores of Study 2

Mean (SD)
F
Nicotine boost
CO boost
Heart Rate boost
Topography
Puff Number
Inter-puff-interval
Puff Volume

P

Ultra Light

Full Flavor

A1 Sham

21.9 <.001
24.4 <.001
18.5 <.001

4.0 (3.7)"
2.4 (1.3)"
7.8 (5.3)"

11.3 (7.1)
5.3 (2.3)
14.5 (7.2)

2.4 (4.2)"
2.8 (1.3)"
6.6 (4.4)"

<l.O
2.1
5.0

10.3 (1.0)
31.0 (2.6)
41.3 (3.8)

10.1 (0.6)
32.3 (2.9)
38.6 (5.3)

10.3 (0.9)
32.9 (3.9)
42.2 (2.9)"

ns
ns
<.05

Direct Effects
Satisfy
Pleasant
Good taste
Bad taste
Dizzy
Calm
Confused
Concentrate
Awake
Less hunger
Sick
Sleepy
Another cig
--

-

-

-

-

N=19
"Indicates significant difference from U.S. full flavor.

Table 10
Mean scores of withdrawal and cravingfor Study 2

Mean (SD)
Time
Withdrawal
Hughes Hatsukami items
Urges to smoke
Irr/Frus/Ang
Anxious
Difficulty conc
Restlessness
Hunger
Impatient
Craving a cig/Nic
Drowsiness
DepIFeel blue
Desire for sweets
Tiffany Drobes QSU
Factor 1
Factor 2

F

P

Cigarette
F
P

Time x Cigarette
F
P

Ultra Light
Pre
Post

Full Flavor
Pre
Post

A1 Sham
Pre
Post

Chapter 4
Discussion

As was discussed in previous chapters, there is little information about tobacco
smokers in developing countries and no studies have been published regarding the
cigarette toxicant levels to which these smokers are exposed. Exposure studies are
necessary in order to understand the levels of carcinogens, CO, and nicotine these
smokers receive from cigarettes; this information may help predict disease rates.
Knowledge of nicotine exposure may be particularly important for planning effective
cessation programs for these smokers. This chapter discusses the findings of the two
studies reported here in terms of the:
1. Differences between U.S. and Syrian cigarettes.
2. Differences between U.S. full flavor and ultra light cigarettes.
3. Methods used to compare cigarette toxicant yields to human toxicant exposure.

4. Limitations of the study.
The diflerences between U.S. and Syrian cigarettes: Study 1 (Alhamraa)

In Study 1, the difference observed in the primary outcome measure of expired
CO boost was between U.S. ultra light and the Syrian Alhamraa cigarette: Alhamraa
cigarettes delivered 1.8 ppm more CO to smokers than the U.S. ultra light cigarettes.
There was no significant difference observed between U.S. ultra light and Alharnraa
cigarettes on plasma nicotine boost. There were also no significant differences observed
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between U.S. full flavor and Syrian Alhamraa cigarettes on any primary or secondary
outcome measure except HR.
One explanation for Alhamraa cigarettes exposing smokers to more CO than U.S.
ultra light cigarettes is that they contain no obvious filter vent holes, while U.S. ultra light
cigarettes have filter ventilation holes that dilute the smoke. Although smokers tend to
cover ventilation holes under normal smoking conditions (Kozlowski et al., 1982), these
holes were not occluded in this study. Thus, when participants smoked U.S. ultra light
cigarettes they inhaled partially diluted smoke, but the smoke from Syrian Alhamraa
cigarettes (and U.S. full flavor cigarettes) may not have been diluted. This potential for
differential dilution likely underlies the lower levels of CO exposure observed when
participants smoked U.S. ultra light cigarettes.

In terms of the secondary outcome measures of HR boost, puff topography, and
subjective measures of direct effects and withdrawal, significant differences between the
U.S. brands and Alhamraa were observed on some measures and not others. For
example, significant differences were observed on HR boost between U.S. full flavor and
Alhamraa cigarettes. Participants' HR boost increased 2.4 bpm more, on average, after
smoking U.S. full flavor cigarettes than after smoking Alhamraa cigarettes. Though the
Alhamraa cigarettes exposed smokers to more nicotine (which can increase HR) than
U.S. ultra light cigarettes, the HR boost did not differ between these two cigarette brands.
Explanations for the failure to observe differences in HR between the U.S. ultra light and
Alhamraa in the presence of differential nicotine exposure may involve ceiling effects for
nicotine-induced tachycardia, andlor acute tolerance to nicotine's cardiovascular effects.

68
The notion that there is a ceiling effect to nicotine-induced tachycardia is supported by
the observation that the HR increases observed after 21 mg and 42 mg nicotine patch
application sometimes do not differ (e.g., Evans, Weaver, Collins, & Eissenberg, 2005)
while acute tolerance to nicotine's cardiovascular effects is commonly observed in
tobacco users (e.g., Perkins, Grobe, Mitchell, Goettler, Caggiula, Stiller, et al., 1995; Gire
& Eissenberg, 2000).

For puff topography measures, P I and number of puffs were quite similar across
the three types of cigarettes, but the mean puff volume observed when participants were
smoking U.S. full flavor cigarettes was less than that observed when participants were
smoking U.S. ultra light or Alharnraa cigarettes. This difference, however, was within
the +I- 3 ml limits that were allowed in this procedure and was not significant when the
means were compared using the Tukey's HSD. Overall, the fact that IPI, puff number,
and puff volume were within the proscribed limits suggests that participants
demonstrated that the study methods (auditory and visual feedback) were sufficient for
them to learn to control their smoking behavior.
On measures of the direct effects of smoking, significant differences were
observed when participants rated the taste and pleasantness of the cigarettes after
smoking U.S. full flavor and Alharnraa cigarettes. Participants rated the U.S. full flavor
cigarettes as better tasting and more pleasant than the Alharnraa cigarettes.
Finally on most withdrawal measures, no differences were observed when
participants rated withdrawal symptom severity after smoking U.S. full flavor, U.S. ultra
light, or Alhamraa cigarettes. One exception was the "Urges to smoke" item from the
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Hughes-Hatsukami questionnaire. Participants rated their urges to smoke lower after
smoking the U.S. full flavor cigarettes than after smoking Alhamraa cigarettes.
These observed differences in subjective ratings may be explained by the higher

FTC determined yields of tar per cigarette in the Alhamraa brand relative to the U.S. full
flavor brand. Participants' possible exposure to these higher tar levels under the
conditions of this study may have caused them to rate Alhamraa cigarettes as tasting bad
and being less pleasant than the U.S. full flavor cigarettes. Another possible explanation
is that the participants in this study were selected based upon their self-reported
preference for U.S. full flavor cigarettes. Thus, the observed ratings on direct effects
measures and withdrawal suppression may reflect this selection criterion.
Overall, results reported here suggest that the U.S. ultra light and Alharnraa
cigarettes differ in toxicant exposure: when smoked under controlled topography
conditions, Alhamraa cigarettes expose smokers to higher levels of CO than U.S. ultra
light cigarettes. In contrast, under the conditions of the study, U.S. full flavor and
Alhamraa cigarettes were similar in toxicant exposure: no differences were observed in
nicotine or CO exposure. While Alhamraa cigarettes are not labeled or advertised in
Syria as a specific type of cigarette (e.g. full flavor vs. ultra light, etc.), this brand may be
best categorized as a "full flavor" product based on both its FTC determined constituent
yields and its exposure to smokers of those constituents when smoking topography is
controlled.
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The differences between U.S. and Syrian cigarettes: Study 2 (A1 Sham)
In Study 2, significant differences were observed on primary measures of plasma
nicotine and CO boost when participants smoked U.S. full flavor brand cigarettes versus
Syrian A1 Sham cigarettes. Specifically, significant differences in plasma nicotine boost
and expired air CO boost were observed after participants smoked U.S. full flavor and A1
Sham cigarettes, with U.S. full flavor cigarettes delivering, on average, 8.9 nglml more
nicotine and 2.5 ppm more CO to smokers than the A1 Sham cigar&tes.
In contrast, participants were exposed to similar levels of nicotine and CO when
smoking U.S. ultra light and A1 Sham cigarettes. These results suggest that A1 Sham
cigarettes are more like U.S. ultra light cigarettes than full flavor cigarettes, at least under
the conditions reported here. Interestingly, the Syrian cigarette market does not
differentiate between cigarettes using the full flavorlultra light terminology, though the
A1 Sham cigarettes are considered to be less preferred than Alhamraa cigarettes (Dr. W.
Maziak, personal communication).

In terms of the secondary outcome measures of HR boost scores, puff topography,
and subjective measures of direct effects and withdrawal, significant differences were
observed between the U.S. full flavor and A1 Sham cigarettes. For example, participants'

HR increased, on average, 7.9 bpm more when smoking U.S. full flavor cigarettes than
when smoking A1 Sham cigarettes. In contrast, observed tachycardia was similar when
participants were smoking U.S. ultra light and A1 Sham cigarettes.
For puff topography measures, P I and number of puffs were quite similar across
the three types of cigarettes, but the puff volume observed when participants were
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smoking U.S. full flavor cigarettes was 3.5 ml lower than that observed when participants
were smoking A1 Sham cigarettes. The observed difference in mean puff volumes
between the U.S. full flavor and A1 Sham cigarettes was significant when the differences
were compared using Tukey's HSD. The puff volume for the U.S. full flavor cigarette,
however, is within the +I-3 ml limits that were allowed in this procedure. Overall, the
fact that IPI, puff number, and puff volume were within the proscribed limits suggests
that the study methods (auditory and visual feedback) were sufficient for participants to
learn to control their smoking behavior.
On the direct effects of cigarettes measure, there was an observed difference of
participant ratings between U.S. full flavor and A1 Sham cigarettes. Specifically,
participants' ratings were higher on the questions of feeling dizzy and feeling sick after
smoking the U.S. full flavor cigarettes than after smoking A1 Sham cigarettes. Though
A1 Sham cigarettes contain similar toxicant yields to U.S. full flavor cigarettes (as
measured by the FTC method, see Table 6), participants may be exposed to lower levels
of toxicants when smoking A1 Sham cigarettes than when smoking U.S. full flavor
cigarettes when topography conditions are controlled as in this study. Participants'
exposure to toxicants when smoking A1 Sham cigarettes, as discussed in previous
sections, was more similar to their toxicant exposure when smoking U.S. ultra light
cigarettes. As inhalation into the lungs was not controlled for, it is possible that
participants did not inhale the smoke from A1 Sham cigarettes into their lungs. Low
exposure levels of CO observed after smoking this brand support this inference.
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Participants' exposure to lower levels of nicotine and CO may reduce their ratings of
dizzy and sick after smoking A1 Sham.

In terms of subjective withdrawal, the difference in scores between U.S. full
flavor and A1 Sham on the question of "Urges to smoke" was nearly significant.
Participants reported lower urges to smoke after smoking U.S. full flavor cigarettes than
after smoking A1 Sham cigarettes. As participants were exposed to higher levels of
nicotine and other toxicants when smoking U.S. full flavor cigarettes, their urges to
smoke were suppressed more effectively than when smoking cigarettes which contain
lower levels of nicotine and other toxicants, such as A1 Sham cigarettes. However,
studies have shown that stimuli other than smoke toxicants, such as olfactory and
sensorimotor stimuli, can effectively suppress withdrawal for short periods of time
(Baldinger et al., 1995; Pickworth, Fant, Nelson, Rohrer, & Henningfield, 1999).
Overall, results reported here suggest that the U.S. full flavor and A1 Sham
cigarettes differ in toxicant exposure: when smoked under controlled topography
conditions, U.S. full flavor cigarettes expose participants to higher levels of nicotine and
CO than A1 Sham. In contrast, under the conditions of the study, the U.S. ultra light and
A1 Sham cigarettes were similar in toxicant exposure: no differences were observed in
nicotine and CO exposure. While A1 Sham cigarettes are not labeled or advertised in
Syria as a specific type of cigarette (e.g. full flavor vs. ultra light, etc.), this brand could
categorized in the U.S. market as a "full flavor" product based on its FTC determined
yield of tar, nicotine and CO. A1 Sham cigarettes' exposure to smokers of nicotine and
CO when smoking topography is controlled, however, more closely resembles that of an

73
ultra light. This discrepancy between yield and exposure highlights the need for
understanding the relationship between FTC method constituent yields and smokers'
actual constituent exposure under a variety of conditions.
The digerences between U.S. full flavor and ultra light cigarettes: Studies 1 and 2
In Studies 1 and 2, significant differences were observed on measures of plasma
nicotine and expired air CO when participants smoked U.S. full flavor and ultra light
cigarettes. Specifically, participants' nicotine (6.5 ng/ml Study 1 and 7.3 ng/ml Study 2)
and CO boost (2.6 ppm Study 1 and 2.9 ppm Study 2) were greater when smoking the

U.S. full flavor than when smoking the ultra light cigarettes (3.9 ng/ml Study 1 and 4.0
ng/ml Study 2 nicotine boost and 2.7 ppm Study 1 and 2.4 ppm Study 2 CO boost).
These observed differences in nicotine and CO exposure may be explained by the
uncovered filter vent holes in the ultra light cigarettes used in this study - covering vent
holes, as often occurs during natural smoking (Kozlowski et al., 1982), may increase ultra
light cigarette smokers' nicotine and CO exposure, relative to the values reported here.
However, the more controlled conditions reported here, where topography variables were
fixed and filter vent holed were not covered demonstrates that, in some cases, ultra light
cigarettes can lead to less toxicant exposure than full flavor cigarettes.
In terms of the secondary outcome measures of HR boost, puff topography, and
subjective measures of direct effects and withdrawal, significant differences were
observed between the U.S. full flavor and ultra light cigarettes on some measures. For
example, when smoking U.S. full flavor cigarettes, participants' HR increased an average
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of 3.1 bpm (Study 1) or 6.7 bpm (Study 2) relative to when they smoked ultra light
cigarettes. The increase in participants' HR likely reflects greater nicotine exposure.
For puff topography measures, all variables were quite similar across these two
types of cigarettes. Importantly, under more natural smoking conditions (i.e., when puff
topography variables are free to vary), full flavor smokers who switch to ultra light
cigarettes often take more or larger puffs with the ultra light brand, relative to their usual
full flavor brand (Zacny & Stitzer, 1988; West & Gossop, 1994).
On measures of the direct effects of cigarettes in Study 1, participants' ratings of
good taste were an average of 23.1 points higher after smoking U.S. full flavor cigarettes
than after smoking ultra light cigarettes (See table 7). However, no significant
differences were observed between these cigarettes on this item in Study 2 (See table 9).
In Study 2, participant's ratings of dizzy and sick were 36.6 and 11.4 points higher after
smoking U.S. full flavor than after smoking ultra light cigarettes, and no significant
differences were observed between these cigarettes on these items in Study 1 (See tables
9 and 7).
On subjective measures of withdrawal, participants' ratings of urges to smoke
were 14.4 points lower after smoking U.S. full flavor cigarettes than after smoking ultra
light cigarettes in Study 1 (See table 8). However, no significant differences were
observed between these cigarettes on this item in Study 2 (See table 10). Participants'
post-smoking ratings of irritability/frustration/anger and restlessness were 14 and 22
points lower after smoking U.S. ultra light cigarettes while there was no observed
significant drop in pre- to post-smoking scores on these items after smoking full flavor
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cigarettes in Study 1. No significant differences between pre- to post-smoking scores for
either cigarettes were observed on these items in Study 2. Also, there were no observed
significant differences between the cigarettes on these items in Study 2 (See tables 8 and

Overall, results reported here suggest that the U.S. full flavor and ultra light
cigarettes differ in toxicant exposure: when smoked under controlled topography
conditions, U.S. full flavor cigarettes expose smokers to higher levels of nicotine and CO
than ultra light cigarettes (See tables 7 and 9). In contrast, under the conditions of the
study, the U.S. full flavor and ultra light cigarettes were similar in withdrawal
suppression on some items and not others: significant differences in ratings of taste
observed in Study 1 were not found in Study 2 and significant differences in ratings of
sick and dizzy observed in Study 2 were not found in Study 1. The observation that U.S.
full flavor and ultra light cigarettes differed significantly on only a few subjective
measures with effects that were not observed across both studies (i.e., direct effects,
withdrawal suppression) but differed significantly on all measures of toxicant exposure
(i.e., nicotine, CO) across both studies suggests that the oft-noted brand-induced changes
in puff topography may not be related to inadequate withdrawal suppression, and may
require further study.
The methods used to compare cigarette toxicant levels to human toxicant exposure

The FTC's machine smoking method is an effective way to determine the toxicant
yield of cigarettes under a specific set of rather arbitrary and non-natural smoking
conditions. As these qualifiers imply, the FTC method does not reveal the level of
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toxicants to which cigarette smokers will be exposed, because smokers' topography and

other factors (i.e., coverage of filter vent holes) can vary. Because smokers can alter their
topography and machines cannot, clinical research (i.e., research with smokers) is
necessary if the toxicant exposure of cigarettes is to be understood completely. One type
of clinical research involves ad lib smoking behavior (i.e., allowing puff topography to
vary, and using it as an outcome measure; Woodward & Tunstall-Pedoe, 1992; Sweeney
et al., 1999; Breland et al., 2003) while the current study involved keeping puff
topography fixed in order to understand cigarette effects under specific smoking
conditions. Unlike machine smoking, which does not address smokers' toxicant
exposure under anv conditions, this study demonstrated that smokers of some Syrian
cigarettes are likely exposed to similar levels of CO and nicotine as are U.S. smokers.
Also unllke machine smoking, which cannot address the subjective effects produced by
smoking a cigarette, this study demonstrated that U.S. full flavor and ultra light cigarettes
produce similar levels of withdrawal suppression under the controlled laboratory
conditions reported here. Other studies have also controlled topography variables in
order to determine the extent to which filter ventilation hole blocking influences toxicant
exposure (e.g., Zacny et al., 1986). Thus, even when smoking behavior is controlled,
clinical research provides valuable information that cannot be attained with FTC-like
methods. Moreover, the methods reported here can be modified to mimic the FTC
method, or any other smoking parameters of interest, in order to understand the
relationship between machine testing and smokers' toxicant exposure. This methodology
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may be useful in understanding how machine smoking tests will predict human exposure
within a broad range of topography parameters.
Limitations of Studies 1 and 2
These two studies had several limitations, including: 1) a too-brief inter-cigarette
interval, 2) possibility of type I errors, 3) possibility of type I1 errors, 4) topography
variable choice, and 5 ) length of studies.
Inter-cigarette-interval. In order to maximize convenience for participants, this
study was designed to be completed in a single session. As three cigarettes were to be
smoked in one session, a 90-min rest period was scheduled between cigarettes (i.e., a 90
min inter-cigarette interval) to allow toxicant levels (i.e., plasma nicotine, CO) to return
to baseline (i.e., near-zero levels). This inter-cigarette interval was chosen, in part,
because nicotine has a relatively brief half-life (60-120 min, Ahijevych, 1998; Benowitz,
1996). However, 90 minutes does not allow for complete clearance of nicotine, and CO
has a half-life of 4-5 hours in a sedentary adult (Stewart, 1975), so the 90-min intercigarette interval was too short: plasma nicotine and expired air CO levels did not return
to baseline levels in all participants, and thus "nicotine boost" and "CO boost" were
determined instead of using pre- and post-smoking plasma nicotine and expired CO
levels. Obviously, the ideal situation would be for toxicant levels produced after
smoking one cigarette to decline to near-zero before participants smoked the next
cigarette: in this manner, the absolute increase associated with each cigarette could be
measured. Future studies may benefit from a longer inter-cigarette-interval, including the
use of multiple sessions that occur across several days.
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Type I error. The probability of a Type I error, alpha (a),
may be an important

study limitation. A Type I error occurs when the null hypothesis is rejected falsely. This
error may have been made when the null hypothesis that states that the U.S. full flavor
and ultra light cigarettes would expose smokers to the same levels of toxicants, was
rejected as false. Generating multiple F tests (P < .05), as was done for the analysis of
these data, can increase the experimentwise error rate. Tukey's HSD was used to control
this error rate increase. Tukey's HSD is a conservative post-hoc test designed to compare
all possible pairs of means while maintaining the Type I error rate (Hurlburt, 1998).
Following significant F tests, Tukey's HSD results indicated that U.S. ultra light
cigarettes exposed participants to lower toxicant levels than the U.S. full flavor cigarettes
under the conditions of these studies. The fact that these results were observed in Study 1
and Study 2, each of which had a different group of participants, suggests that they

reflect the true state of the world, and are likely not a Type I error.
Type II error. The probability of a Type I1 error also may have been a study

limitation. A Type I1 error occurs when the null hypothesis has not been rejected when it
should have been, and real differences cannot be detected. A Type I1 error may have
been made on any outcomes that were found to be non-significant. One example of a
potential error is that no differences in toxicant exposure between the U.S. full flavor and
Alhamraa cigarettes were detected in Study 1. Another example is that no differences in
toxicant exposure or HR scores between U.S. ultra light and A1 Sham were detected in
Study 2. A larger sample size would have provided more power, thus decreasing the
chances of making a Type I1 error.
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Topography variable choice. The topography parameters used in these studies

were set to the following values: 1,40 ml puff (+I-3 ml) every 30 sec for a total of 10
puffs per cigarette. These parameters were chosen as they were similar to the average of
the most commonly used parameters in smoking studies (Lee et al., 2003). However,
there is great variability in mean topography across studies. For example, though the puff
volume of these smoking studies examined averaged 40 ml, there was a range from 21 rnl
to 66 ml. Also, the average puff number per cigarette was 10 puffs but the range was
from 8-16 puffs (Lee et al., 2003). Future studies may want to manipulate topography
variables systematically in order to characterize better the nicotine and CO exposure that
cigarettes produce.
Length of studies. These two studies were short-term in order to evaluate

smokers' exposure to CO and nicotine associated with one cigarette over several hours.
The ability of smokers to extract CO and nicotine may change over time and some
toxicants, such as carcinogens, require longer evaluation periods to detect changes. Thus,
a complete evaluation of a cigarette's toxicant exposure to humans may require longerterm studies with repeated cigarette administration.
Summary

Twenty-one and 19 daily, full flavor cigarette smokers completed one 4.5 hour
session in which they smoked three cigarettes, each separated by 90 min. The Latin
square ordered cigarettes were U.S. full flavor, U.S. ultra light and either Syrian
Alharnraa (Study 1) or A1 Sham (Study 2). These two studies examined the short-term
toxicant exposure to participants from these cigarettes of varying toxicant yields. As
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smokers tend to change their smoking behavior when given cigarettes of varying yields,

topography measures of puff number, volume and IPI were held constant to allow for a
controlled comparison of the toxicant exposure participants received from these different
cigarettes. Toxicant yield and exposure were similar for some cigarettes and not others
under these controlled conditions (i.e., controlled topography measures and no filter vent
blocking). For example, Alhamraa cigarettes were more similar to U.S. full flavor
cigarettes in terms of nicotine and CO exposure. On the other hand, A1 Sham cigarettes
were more similar to U.S. ultra light cigarettes in terms of nicotine and CO exposure and
changes in HR.
Even when toxicant yield and exposure were significantly different (i.e., U.S. full
flavor vs. U.S. ultra light), few significant differences were observed on subjective
reports of direct effects and withdrawal for these cigarettes and none of these differences
were observed across both studies. Overall, these results emphasize the value of clinical
research for understanding the smoke toxicants to which smokers of different cigarettes
are exposed.
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Appendices
Appendix A - Telephone Screening
Telephone Screening
Date
Interviewer

I

Eligibility: Coordinator circle and initiavdate

Patch
Patch 2
International
PREP

Eligible
Eligible
Eligible
Eligible

Not Eligible
Not Eligible
Not Eligible
Not Eligible

Interviewer: "I would like to ask you some questions about yourself and your health
status as well as your use of nicotine, alcohol, and other drugs. The purpose of these
questions is to determine whether or not you are eligible to participate in either the
studylstudies I just described or in any of the other studies being conducted in the lab.
All of your responses are confidential. You are not required to answer any question and
you may stop this interview at any time. May I begin the questions?"
Document caller's response by circling either:

Yes

or

No

If Yes: begin form. If No: thank caller for calling.
How did you hear about uslour studies?

Personal Information:
1. "What is your first name?"
2. "What is a phone number at which you can be contacted?"

3. "What timelday is best to call you?"
4. "If we call and you are not available, may we leave a message?"
Circle Yes or No
5. "What is your date of birth?"

6. "What is your height?"

(feet and inches)

7. "What is your weight?"

(pounds)

8. "Did you graduate high school or obtain a GED?"

[Note to interviewer: If yes, please note which one]

Circle Yes

or

No

92
9. "How many years of education have you completed?"
(e.g., 12 yrs = high school diploma; 16 yrs = college degree)

(years)

General health status:
10. "Are you under a doctor's care for a medical condition?" Circle

Yes

or No

Yes

or No

If Yes: "Please describe the condition":
11. "Are you taking any prescription or over-the-counter medications?"
Circle Yes or No

If Yes: "Please identify the medication":
12. "Do you have any chronic health concerns or problems?" Circle

If Yes: "Please describe the concern or problem":
13. Do you have any heart conditions?

Circle

Yes

or

If Yes: "Please describe the condition":
14. Do you have any psychiatric conditions like depression or anxiety?
Circle Yes or No

If Yes: "Please describe the condition":
15. "Have you ever been diagnosed with high or low blood pressure?"
Circle Yes or No

If Yes: "Please indicate whether it is high or low":
16. "Do you have fainting spells?"

Circle Yes

or

No

17. "Do you have seizures?"

Circle Yes

or

No

18. "Do you have any kidney problems?"

Circle Yes

or

No

Cigarette use:
19. "Do you smoke tobacco cigarettes?"

Circle Yes

or

No

If No: Skip the remainder of this section.
20. "What brand of cigarettes do you smoke?''
Circle:
Regular/Light/Ultra light
Non-mentholMentho1

No

21. "Hard pack or soft pack?"

22. "Regular or 100s?"
23. "Have you ever felt a need to cut down or control your smoking,
but had difficulty doing so?"
Circle Yes

or

No

24. "Do you ever get annoyed or angry with people who criticize your
smoking or tell you that you ought to quit smoking?" Circleyes

or

No

25. "Have you ever felt guilty about your smoking or about something
you did while smoking?"
Circle Yes

or

No

26. "Do you ever smoke within half an hour of waking up (eye-opener)?"
Circle Yes or

No

27. "How many cigarettesfday do you smoke?"

(num of cigs)

mote to interviewer: Please note the exact number of
cigaretteslday smoked, and ALSO circle
]
the appropriate group-

28. "For how long have you smoked this number?"

10 or less
11-20
21-30
3 1 or more
(mnths or yrs)

29. "How soon after you wake up do you smoke your first cigarette?" Circle:
Within30 min.
After 30 min.
30. "Do you find it difficult to refrain from smoking in places where it
is forbidden (e.g., at the library, at the movies)?"
Circle Yes or No
3 1. "Which cigarette would you hate to give up the most?" Circle: IS' in the morning
Any other
32. "Do you smoke more frequently during the first hours after
Circle Yes
awakening than during the rest of the day?"

or

No

33. "Do you smoke if you are so ill that you are in bed most of the day?"
Circle Yes or

No

Smokeless Tobacco Use:
34. "Do you use smokeless tobacco (i.e., snuff, dip, or chew)?" Circle

Yes

or No

If No: Skip the remainder of this section.
35. "What brand of smokeless tobacco do you use?"
36. "How many timeslday do you use smokeless tobacco?"
37. "For how long have you used smokeless tobacco?"

(mnths or yrs)

Interviewer: "I'd like to ask you some additional questions about your use of alcohol
and other drugs."
Alcohol use:
38. "Have you ever been treated for alcohol abuseldependence?"
Circle Yes or No
39. "Do you use (drink) alcoholic beverages?"

Circle Yes

or

No

If Question #39 is No: Skip the remainder of this section.
40. "Have you ever felt you ought to cut down on your drinking?" Circle Yes
41. "Have people annoyed you by criticizing your drinking?" Circle Yes
42. "Have you ever felt bad or guilty about your drinking? Circle Yes
43. "Have you ever had a drink first thing in the morning to steady
your nerves or get rid of a hangover (eye-opener)?" Circle Yes or

or No

or No
or

No

No

44. "How many alcoholic drinks (by alcohol I mean beer, wine, or liquor)
do you have on a typical day?
(num of drinks)
45. "How many days out of the last 30 have you used alcohol?"

(num of days)

Marijuana use:
46. Have you ever, in your lifetime, smoked marijuana or hashish?
Circle Yes or No
If No: Skip the remainder of this section.
47. "Have you smoked marijuana within the past month?" Circle Yes

If No: Skip to question 54.

or

No
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48. "Have you ever felt a need to cut down or control your smoking of marijuana,
but had difficulty doing so?"
Circle Yes or No
49. "Do you ever get annoyed or angry with people who criticize your
marijuana smoking or tell you that you ought to quit smoking?"
Circle Yes

or

No

50. "Have you ever felt guilty about your marijuana smoking or
about something you did while smoking?"
Circle Yes

or

No

5 1. "Do you ever smoke marijuana within half an hour of waking up (eye-opener)?"
Circle Yes or No
52. "How many days out of the last 30 have you smoked marijuana?"
days)

(num of

53. "Can you estimate how much money you spend each month on marijuana?"
(dollars)
54. "Have you ever received medical treatment related to your marijuana use?
Circle Yes or No

.................................................................................

Other drug use:
55. "Have you used any other illicit drugs within the past month?"
Circle Yes

or

No

If Yes: "Please identify which drug or drugs."
For women only:
56. "Are you currently pregnant?"

Circle Yes

or

No

57. "Are you currently breast-feeding a child?"

Circle Yes

or

No

58. "Which contraceptive method(s) are you currently using
(including abstinence)?"
59. "What was the first day of the onset of your last period?"

Interviewer: "Thank you for responding to these questions. I need to pass on your
responses to the principal investigator who will then determine whether or not you are
eligible to participate in a study; someone will contact you within approximately two
working days if you are eligible. If you are not eligible for any of our current studies,
then you will not be contacted."
[if respondent does not have a phone, they can call us back in a few days]

Additional studies
60. "Even if you are not eligible for one of our current studies, may we call you
sometime in the future if there are additional studies for which you are qualified?"
Document caller's response by circling either:

Yes

or

No

Appendix B - Informed Consent Form

Title. International cigarette comparison study

VCU IRB Protocol Number. 2898
Investigator. Dr. Thomas Eissenberg
Purpose of the study. The purpose of this research study is to determine the effects of
different types of cigarettes, some from the U.S. and some not from the U.S.
Description of the study. This study involves determining the mood and physiological
effects of cigarettes marketed in the U.S. and abroad. You will be asked to learn to take
puffs of a specific size and then take 10 puffs each from three different cigarettes during
an approximately 4-hour session.
Procedures. If you agree to join the study, we will ask you to practice some of the
study procedures and then complete a single, approximately 4-hour session.
The study procedures that you will practice involve completing some computerized
questionnaires and learning how to take puffs of a certain size from an unlit cigarette.
A computer will help you learn to take the.correct sized puffs. We will need to teach
you to take the correct size puffs before you can participate in the 4-hour session. We
can practice the study procedures today, or we can schedule another day for the
practice. The practice period should take less than one hour, and we will pay you $50
for completing it.
Once you have learned the study procedures, we will schedule a time when you can
come back to the laboratory and complete an approximately 4-hour session. Before the
session we will ask you to abstain from smoking for at least 8 hours. For example, you
may begin the session in the morning if you have not smoked since dinnertime the day
before. Before the session we will test your breath to find out when you last smoked;
the result of this test will determine if the session can begin. If the breath test indicates
that a session may not begin, you may wait or reschedule the session for another day.
At the beginning of the session a research nurse will insert a thin needle into your arm
(catheter) that will stay there for the duration of the session. This needle will be used to
draw blood (about a tablespoonful) periodically. We use this method because
participants tell us that it is more comfortable than repeated "sticks" with a needle
whenever we need a blood sample. Although we will take as many as six blood samples
in each session, the total that we take is less than 1/4 of what is taken when you donate
blood. Once the catheter is inserted, we will begin monitoring your heart rate with a
small cuff placed over your finger, and ask you to practice the study puffing procedures
one more time (from an unlit cigarette).

Each session will involve you taking puffs from lit cigarettes at three different times, with
about 90 minutes of rest between each smoking time. The cigarettes will be either
normally marketed U.S. cigarettes, or cigarettes that are marketed to smokers in another
country. They may or may not be your own brand of cigarettes. Each time that you
smoke you will take exactly 10 puffs from the cigarette; a research assistant and the
computer will help you keep track of the number of puffs that you take. Also, the
computer will tell you when to take each puff and will help you make sure that the puffs
that you take are the same size.
Before and after each of the three smoking periods we will take a blood sample from the
catheter and ask you to respond to some computerized questionnaires about your mood
and the taste and other effects of the cigarette. We will also measure the amount of
smoke in your breath. We will be monitoring your heart rate throughout the session.
After the third smoking period and all measurements are completed, the nurse will
remove the catheter from your arm and you will be paid $130 for your time. This
payment will end your study participation.

Risks and Discomforts. There are minimal risks associated with this study. Eight or
more hours of cigarette abstinence may cause mild discomfort that is not medically
dangerous. The blood drawing procedure involves minimal risks of infection that are
reduced by the research nurse who will use sterile, disposable equipment. If you find any
effects or data collection procedures unacceptable, you may stop your participation at any
time.
As the study procedures might injure an unborn child, pregnant women may not
participate.
You will be made aware of any significant new findings that may change your decision to
remain in this study.

Benefits. This is not a treatment study, and you are not expected to receive any direct
medical benefits from your participation in the study. The information from this research
study may lead to better understanding of the effects of different brands of cigarettes.
Costs. There are no financial costs to you for participating in this research study.
Participating will take about 4-5 hours of your time. You will be paid for your time and
inconvenience.
Payment for participation. You will be paid $180 if you complete the entire study
(practice and session). If you withdraw from the study before completion, you will be
paid $5/hour for the time that you spent in the laboratory.

Alternative Treatment. This is not a treatment study. Your alternative is not to
participate in this study.
Confidentiality. Confidentiality of personal information about you - including your
medical records and personal research data gathered in connection with this study - will
be maintained in a manner consistent with federal and state laws and regulations.
You should know that research data or (medical information if applicable) about you may
be reviewed or copied by Virginia commonwealth University or the U.S. Department of
Health and Human Services. Although results of this research may be presented at
meetings or in publications, identifiable personal information pertaining to participants
will not be disclosed.

Compensation for Injury. Virginia Commonwealth University and the VCU Health
System (formerly known as Medical College of Virginia Hospitals) have no plan for
providing long-term care or compensation in the event that you suffer injury as a result of
your participation in this research study.
If you are injured or if you become ill as a result of your participation in this study,
contact your study doctor immediately. Your study doctor will arrange for short-term
emergency care or referral if it is needed.
Fees for such treatment may be billed to you or to appropriate third party insurance.
Your health insurance company may or may not pay for treatment of injuries as a result
of your participation in this study.

Voluntary Participation and Withdrawal. Your participation in this study is
voluntary. If you do participate, you may freely withdraw from the study at any time.
Your decision will not change your future medical care at this site or institution.
Your participation in this study may be stopped at any time by the study doctor without
your consent. The reasons might include:
the study doctor thinks it necessary for your health or safety;
you have not followed study instructions;
administrative reasons require your withdrawal.
If you decide to withdraw from this study or if you are withdrawn by the study doctor, we
will pay you for the time you spent in the study.

Questions. In the future, you may have questions about your study participation. You
may also have questions about a possible side effect, or a possible research-related injury.
If you have any questions, contact:

Dr. Thomas Eissenberg
VCU Box 980205
Richmond Virginia, 23298-0205
Telephone: (804) 827-3562.

Subjects' Rights Information. If you have questions about your rights as a research
subject, you may contact:
Office for Research Subjects Protection
Virginia Commonwealth University
800 East Leigh Street, Suite 111
P.O. Box 980568
Richmond, VA 23298
Telephone: 804-828-0868
Do not sign this consent form unless you have had a chance to ask questions and have
received satisfactory answers to all of your questions.

Consent. I have been provided with an opportunity to read this consent form carefully.
All of the questions that I wish to raise concerning this study have been answered.
By signing this consent form, I have not waived any of the legal rights or benefits, to
which I otherwise would be entitled. My signature indicates that I freely consent to
participate in this research study.

Participant's Printed Name

Signature of Participant

Date

Signature of Person Performing Consent

Date

Signature of Witness to Consent

Date

Signature of Investigator

Date

Appendix C - Personal Information and Health Status Form
Physical Information
International Cigarette Comparison

1

I

Participant's ID
-

-

Screening CO

PPm

Screening Weight

Ibs (no shoes)

Screening Height

feet and

Date
-

-

inches (no shoes)

I

Appendix D - Demographic Information
Demographic Information
International Cigarette Comparison Study

Participant's Name

Today's Date

Age
Years:

Exact date of birth

Ethnicity
o Hispanic or Latino

o Not Hispanic or Latino

Race
o American IndianJAlaskan Native o AsianINative Hawaiian or other Pacific Islander
o Black or African American

Gender
o Male

o White

o OtherKJnknown (

)

o Female

Marital status
o Single o Married
Education
Years:

o Separated

o Divorced

o Widowed

(For example, High school = 12, College degree = 16, etc.)

Primary employment
o unemployed

o PT (0-30 hrslwk)

o FT (>30 hrslwk)

o Student

History of quit attempts
times o Trying to quit now

o Never tried to quit o Tried to quit

Previous experience with nicotine medications
o No experience

o At least one experience

o Nicotine gum

o Nicotine patch

o Nicotine spray

o Nicotine inhaler

By signing this form below, you indicate that you have answered the above questions truthfully.

Participant's Signature

Today's Date

Investigator's Signature

Today's Date

Appendix E - Fagerstrom Test for Nicotine Dependence
Smoking Behavior
International Cigarette Comparison

1

Participant's ID

Today's Date

Please answer the following questions (mark an X in one box only):
1. How soon after you wake up do you smoke your first cigarette?
Within
5 minutes

Within
6-30 minutes

Within
3 1-60 minutes

After
60 minutes

2. Do you find it difficult to refrain from smoking in places where it is forbidden (e.g.,
in church, at the library, at the movies)?
Yes

No

3. Which cigarette would you hate to give up the most?
The first one in the morning

All others

4. How may cigarettes a day do you smoke?
10 or less

11-20

21-30

3 1 or more

5. Do you smoke more frequently during the first hours after waking than during the rest
of the day?
Yes
No

6. Do you smoke if your are so ill that you are in bed most of the day?
Yes
No

104
Appendix F - Nicotineltobacco withdrawal VAS (Hughes & Hatsukami, 1986)

Not at all
1. URGES to smoke

2. Irritability/frustration/anger

3. Anxious

4. Difficulty concentrating

5. Restlessness
6. Hunger

7. Impatient

8. CRAVING a cigarettelnicotine

9. Insornnialdisturbed sleep

10. Increased eating

11. Drowsiness

Extremely

Appendix G - Questionnaire of Smoking Urges (Tiffany & Drobes, 1991)

1. Smoking would make me feel very
good right now.

0000000
Strongly
disagree

2. I would be less irritable now if I
could smoke.

0
Strongly
disagree

3. Nothing would be better than
smoking a cigarette right now.

5. I will smoke as soon as I get the
chance.

Strongly
disagree

8. Smoking would not help me calm

Strongly
agree

Strongly
agree

0000000
Strongly
agree

0000000
Strongly
disagree

7. Smoking would make me less
depressed.

Strongly
agree

0000000

Strongly
disagree

6. I don't want to smoke right now.

~

0000000
Strongly
disagree

4. I am not missing smoking right now.

Strongly
agree

Strongly
agree

0000000
Strongly
disagree

Strongly
agree

0000000
Strongly
disagree

Strongly
agree

down right now.

9. If I were offered a cigarette, I would
smoke it immediately.

~

~

Strongly
disagree
10. Starting now, I could go without
smoking for a long time.

Strongly
agree

0000000
Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

11. Smoking a cigarette would not be
pleasant.

12. If I were smoking this minute, I
would feel less bored.

13. All I want right now is a cigarette.

14. Smoking right now would make
me feel less tired.

~

~
Strongly
agree

Strongly
disagree
15. Smoking right now would make me
feel happier now.

0
Strongly
disagree

16. Even if it were possible, I probably
wouldn't smoke right now.

0
Strongly
disagree

17. I have no desire for a cigarette right

~

0

~
Strongly
agree

~
Strongly
agree

~~~0~~~
Strongly
disagree

Strongly
agree

0

~

now.

18. My desire to smoke seems overwhelming.
Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

19. Smoking right now would make
things seem just perfect.

20. I crave a cigarette right now.

21. I would not enjoy a cigarette right
now.

22. A cigarktte would not taste good
right now.

23. I have an urge for a cigarette.

~
Strongly
disagree

24. I could control things better right
now if I could smoke.

~
Strongly
disagree

25. I am going to smoke as soon as
.- -

Strongly
agree

~
Strongly
agree

0000000
Strongly
disagree

26. I would not feel better physically if I

~

Strongly
agree

~~~~~~~
Strongly
disagree

Strongly
agree

were smoking.

27. A cigarette would not be very
satisfying right now.

0000000
Strongly
disagree

28. If I had a lit cigarette in my hand I
probably would not smoke it.

Strongly
agree

0000000
Strongly
disagree

29. If I were smoking right now I could
think more clearly.

0
Strongly
disagree

30. I would do almost anything for a
cigarette
now.
-

32. Right now, I am not making plans to
smoke.

0

~
Strongly
agree

0000000
Strongly
disagree

3 1. I need to smoke now.

Strongly
agree

~

Strongly
agree

~

Strongly
disagree

Strongly
agree

Strongly
disagree

Strongly
agree

~~~~~~~

0

Appendix H - Direct Effects of Cigarettes Scale

1. Was the cigarette satisfying?

2. Was the cigarette pleasant?

3. Did the cigarette taste good?

4. Did the cigarette taste bad?

5. Did the cigarette make you dizzy?
6 . Did the cigarette calm you down?
7. Did the cigarette make you feel confused?

8. Did the cigarette help you concentrate?

9. Did the cigarette make you feel more awake?

10. Did the cigarette reduce your hunger for food?

11. Did the cigarette make you sick?

12. Did the cigarette make you sleepy?

13. Would you like to smoke another
cigarette RIGHT NOW?

I

I

*
8
c

0
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